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 Tissue stem cells balance fate decisions of self-renewal and differentiation to maintain 
homeostasis over the lifetime of an organism, as well as to repair tissues upon injury and wounding. 
Disrupting the balance between self-renewal and differentiation results in pathology: excessive 
self-renewal at the expense of differentiation is associated with tumor initiation, whereas failure 
to properly self-renew leads to stem cell exhaustion and aging. Stem cell fate is under tight 
regulation by the surrounding microenvironment, or niche, which includes neighboring cell types, 
signaling molecules, extracellular matrix, and nutrients. While the role of stromal cells and the 
signals they produce has been extensively studied with regards to control of stem cell fate, 
relatively little known is about how tissue stem cells integrate extracellular nutrient availability 
with fate decisions. Moreover, while intracellular metabolic pathways have been shown to regulate 
the balance of self-renewal and differentiation, it remains unknown whether or not endogenous 
metabolic pathways or nutrient availability predispose stem cells towards transformation or control 
their responses to tissue injury.  
Here, I address these questions in epidermal stem cells (EpdSCs), which maintain integrity 
of the skin barrier over an organism’s life. EpdSCs are a cell of origin for squamous cell 
carcinomas (SCCs), amongst the most common and threatening malignancies worldwide. 
Additionally, EpdSCs of the interfollicular epidermis (IFE) and hair follicle (HF) respond to 
injuries in the skin barrier to repair the breach. First focusing on tumor initiation, I find oncogenic 
EpdSCs are serine auxotrophs, whose growth and self-renewal require abundant exogenous serine. 
When extracellular serine is limited in vitro and in vivo, EpdSCs activate de novo serine synthesis, 
which in turn produces the metabolite α-ketoglutarate (αKG). αKG stimulates terminal 
differentiation via activation of αKG-dependent dioxygenases that remove the repressive histone 
modification H3K27me3, which otherwise promotes EpdSC self-renewal. Accordingly, serine 
starvation or enforced αKG production antagonizes SCC initiation and growth. Conversely, 
blocking serine synthesis or repressing αKG-driven demethylation facilitates malignant 
progression in vivo.  
Finally, I extend these findings to stem cell responses to tissue injury. In the epidermis, 
abrasion of the IFE activates HFSCs to repair the breach, which is associated with transient 
hyperproliferation, migration and activation of a plasticity program termed lineage infidelity 
wherein HFSCs undergo a fate switch to become IFE-SCs, fueling regeneration of a non-cognate 
tissue. I find that environmental serine restriction accelerates HFSC-mediated wound repair, which 
I link specifically to acceleration of stem cell plasticity and acquisition of IFE fate. Altogether, 
these findings reveal that extracellular serine is a critical determinant of EpdSC fate and provide 
insight into how nutrient availability is integrated with stem cell fate decisions during tumor 
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 Development and homeostasis of multicellular organisms depends on cells acquiring and 
maintaining the correct fate at the right place and time. Cell fate determination, wherein less 
differentiated cells progressively acquire specific fates and functions, is essential for proper 
embryogenesis and normal development. Even in postnatal life, proper cell fate determination is 
critical for maintenance of tissue homeostasis, which requires stem cells to balance self-renewal 
and differentiation. In both the embryo and postnatal tissues, cell fate determination depends both 
on inductive signals from the environment and the competence of cells to respond appropriately 
to these signals1–3. The landmark discovery of the Spemann-Mangold organizer demonstrated that 
a collection of embryonic cells is sufficient to re-pattern fate determination programs in amphibian 
embryos4. Early in development, factors secreted by the organizer can induce non-neural tissue to 
adopt a neural fate, but this plasticity is lost as development progresses. In postnatal life, inductive 
signals triggered by threats to tissue integrity can drive stem cells to mount proliferative programs 
to restore homeostasis3. Even differentiated cells can be coaxed to respond to inductive signals 
when needed: for example, upon injury to the intestinal stem cell pool, differentiated Paneth cells 
are able to de-differentiate into stem cells, facilitating intestinal repair5.  These examples highlight 
how cell fate changes require precise environmental cues, which interact with cell-state specific 
factors, to shape appropriate cellular outcomes. Accordingly, dysregulation of either extracellular 
cues or their downstream intracellular responses compromise cell fate programs and results in 
diseases ranging from birth defects to cancer 2,3. Consequently, understanding the molecular 
regulation of cell fate decisions is critically important for understanding the mechanistic basis of 
both normal physiology and disease states.  
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 The transcriptional program of a cell is a key determinant of cell identity. The paramount 
importance of transcriptional programs to cell identity is perhaps best highlighted by the 
reprogramming of fully differentiated cells to pluripotent stem cells simply by expressing four key 
pluripotency transcription factors6. Thus, understanding the mechanisms that regulate a cell’s 
transcriptional output is key to understanding cell fate decisions. Transcriptional changes can be 
facilitated by remodeling a cell’s chromatin landscape, and a large body of work has focused on 
the role of chromatin regulation in cell fate decisions 1–3,7. In particular, chemical modifications on 
DNA and histones provide a critical avenue for cells to control activation of gene expression 
programs. These chemical modifications are derived from intermediates of cellular metabolism, 
most notably S-adenosylmethionine and acetyl-CoA, which serve as the donors for methylation 
and acetylation modifications, respectively. Enzymes that remove these modifications often also 
require metabolites as critical co-substrates. Accordingly, fluctuations in the availability of key 
metabolites that modulate activity of chromatin-modifying enzymes are postulated to contribute 
to transcriptional regulation by shaping the chromatin landscape 8–10.  
 Intracellular metabolite levels are responsive to both cell-intrinsic metabolic pathway 
activity as well as extrinsic cues from the microenvironment, including growth factors and nutrient 
availability. Many inputs, including tissue lineage, proliferative status and nutrient availability, 
collectively determine the metabolic demands of individual cells11,12.  Accordingly, recent studies 
highlight that cell-type specific metabolic demands influence cellular proliferation and fate in 
response to microenvironmental changes, including changes in key nutrients 13–15. Emerging 
evidence additionally suggests that tissues experience distinct nutrient microenvironments, and 
that heterogeneity in extracellular nutrients can control cell fate by controlling the availability of 
metabolites that regulate the chromatin landscape 14,16–20. In this manner, intracellular metabolites 
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are emerging as critical components of cell fate determination programs, capable of integrating 
extracellular nutrient status and intracellular biochemical demands to influence transcriptional 
networks and cell fate decisions.  
Here, I review the proposed mechanisms by which select intracellular metabolites integrate 
environmental inputs  to shape pathways determining lineage specific cell fates . I focus on 
metabolic intermediates of the tricarboxylic acid (TCA) cycle, a central regulatory hub of nutrient 
metabolism within cells. Multiple extracellular nutrients can feed into the TCA cycle, although in 
proliferating cells the major TCA cycle fuels are glucose and glutamine (Fig. 1.1a). Several 
intermediates of the TCA cycle, including α-ketoglutarate (αKG), succinate, and fumarate have 
been shown to regulate gene expression programs in various contexts 8,21. Thus, the TCA cycle 
may integrate both extracellular nutrient availability and downstream transcriptional changes 
during cell fate changes. In particular, I discuss evidence that regulation of gene expression and 
cell fate by TCA cycle metabolites is context-dependent, with metabolites acting both upstream 
and downstream of lineage specific signaling and specification programs to shape cell fate. Finally, 
I discuss how nutrient availability creates permissive environments for cell fate outcomes by 






Fig. 1.1: Metabolic regulation of αKG-dependent dioxygenases. a, Schematic of key pathways 
involved in synthesis and break down of αKG, 2HG, fumarate and succinate. Enzymes directly 
involved in αKG metabolism are shown in blue, those involved in 2HG, fumarate and succinate 
metabolism are shown in red. b, Generalized schematic of αKG-dependent dioxygenase (also 
known as 2-oxoglutarate dependent dioxygenase or OGDD) action on your favorite target. 
Dioxygenases cataly ze net demethylation or hydroxylation reactions using αKG and molecular 
oxygen as co-substrates and producing succinate as a by-product. Vitamin C, oxygen and αKG 
have been shown to promote dioxygenase activity, whereas succinate, fumarate and 2HG have 
been shown to suppress their activity. c, Enzymatic assays provide potential insights into metabolic 
regulation of dioxygenase catalytic activity. In this example, dioxygenase B is expected to be 
sensitive to physiological fluctuations in αKG concentrations, whereas dioxygenase A will be less 
sensitive. However, it remains unclear what true physiological αKG concentrations are, given that 
dioxygenases may be sensitive to compartmentalized metabolite pools. 
 
1.2 αKG-DEPENDENT DIOXYGENASES AS METABOLIC MEDIATORS OF CELL 
FATE CONTROL 
Mechanistically, changes in TCA cycle metabolites are postulated to affect cell fate by 
regulating activity of α-ketoglutarate dependent dioxygenases 22,23. The family of αKG-dependent 
dioxygneases comprises over 60 enzymes, including Jumonji C-domain lysine demethylases 
(JmjC-KDMs), which demethylate histones, Ten-Eleven Translocation (TET) DNA 
methylcytosine oxidases, and prolyl hydroxylases, which control collagen biogenesis and hypoxia-
inducible factor (HIF) stability. TCA cycle intermediates serve both as critical co-substrates and 
competitive inhibitors of αKG-dependent dioxygenases: the enzymes consume αKG and 
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molecular oxygen as part of their reaction cycle, yielding succinate and carbon dioxide8. αKG-
dependent dioxygenases are inhibited by other TCA cycle metabolites including succinate and 
fumarate, as well as the related metabolite 2-hydroxyglutarate (2HG), which can exist in cells as 
both a D and L enantiomer (Fig. 1.1b). Mutations in several of the enzymes that are involved in 
the production and breakdown of these metabolites, including isocitrate dehydrogenase (IDH1 and 
IDH2), succinate dehydrogenase (SDH), and fumarate hydratase (FH) have been shown to be 
drivers in cancer by disrupting normal cell fate decisions 21 (Fig. 1.1a). Even absent these 
mutations, however, intracellular abundances of aKG, succinate, fumarate and 2HG have been 
shown to regulate cell fate, including in stem cells, immune cells, and cancer cells 8,21.  
The observation that TCA cycle metabolites can control αKG-dependent dioxygenases and 
cell fate raises major questions, including how a non-specific signal such as TCA cycle 
intermediate abundance can lead to a specific outcome in cell fate.  One possibility is that the effect 
of a change in metabolite abundance is read out by a cell based on the relative affinity of 
dioxygenases for that metabolite. Briefly, the Km of an enzyme for a particular substrate must be 
within the range of physiological fluctuations in concentration of that substrate in order for the 
enzyme’s activity to be significantly affected by changes in substrate levels 8,10 (Figure 1.1c). In 
vitro enzymatic assays suggest that the Km of αKG-dependent dioxygenases for αKG are in the 
low (~1-50) micromolar range, whereas the Ki and IC50 of succinate, fumarate, and 2HG are in the 
upper micromolar to low millimolar range 24. Even within these ranges, however, there is evidence 
for differential effects of metabolites on dioxygenase activity 22,24,25. For example, in vitro studies 
suggest that (L)- but not (D)-2HG inhibits prolyl hydroxylase function 22,25, and even closely-
related dioxygenases can exhibit vastly different affinity for the same metabolite 24,26.  Thus, the 
response to a metabolite may be contingent upon the enzymatic properties of dioxygenases, and it 
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will be of major interest in the future to understand whether the expression patterns of 
dioxygenases with varying affinity for metabolites provides a biochemical rationale for specific 
outcomes driven by metabolic perturbations. 
Nevertheless, there are several important limitations to cell-free systems in understanding 
metabolic control of cell fate. First, kinetic constants determined in simplified settings in vitro may 
not reflect enzyme behavior in a complex environment in vivo. Second, current approaches to 
measure metabolite concentrations provide information on whole cell or tissue abundances, while 
chromatin modifying αKG-dependent dioxygenases may be sensitive only to nucleo-cytosolic 
levels of metabolites, where substrates may be more (or less) limiting 27,28. Suggestively, cancer 
associated IDH mutations (mtIDH), which convert αKG to 2HG, occur in both cytosolic IDH1 and 
mitochondrial IDH2, but mtIDH1 traditionally drives lower production of 2HG than mtIDH2. 
However, 2HG production by mtIDH1 is increased upon ectopic targeting to the mitochondria, 
potentially reflecting limited substrate availability in the cytosol 28. Whether or not nucleo-
cytosolic dioxygenases compete for a limited pool of αKG remains to be explored. 
An additional challenge in understanding how changes in select TCA cycle metabolites 
may coordinately influence cell fate is the fact that multiple dioxygenase-sensitive marks are often 
affected by metabolic changes 29–32. For example, succinate and fumarate accumulation in cancer 
cells is linked to HIF stabilization and hypermethylation of DNA as well as multiple histone lysine 
residues 31,33,34. The ability of a single metabolite to influence multiple relevant pathways 
highlights the importance of these molecules but poses a challenge in understanding which changes 
represent biologically relevant, primary responses. For example, fumarate accumulation in FH 
deficient cells was thought to drive tumorigenesis in the kidney via inhibition of PHDs and 
subsequent stabilization of HIFs. However, double knockout of HIF1α and HIF2α did not prevent 
 8 
FH-loss induced renal cyst formation, which was instead dependent on hyper-activation of NRF2 
signaling driven not by fumarate-mediated inhibition of αKG-dependent dioxygenases but rather 
by direct covalent modification of reactive cysteines on KEAP1, a major negative regulator of 
NRF2 35. Indeed, many studies provide evidence that metabolites regulate cell fate decisions and 
dioxygenase-sensitive marks but remain correlative with regards to the precise mechanisms by 
which these effects are mediated.  
The most rigorous approach to studying metabolic control of cell fate will involve both 
cell-free biochemical studies and genetic experiments in relevant in vivo systems. This combined 
approach recently revealed a critical role for molecular oxygen in muscle differentiation. αKG-
dependent dioxygenases consume oxygen as part of their reaction cycle, and therefore may directly 
respond to hypoxia. The authors found that hypoxia impaired myogenic differentiation by 
inhibiting the αKG-dependent H3K27me3 demethylase UTX, which has a low in vitro oxygen 
affinity. Notably, the closely related H3K27me3 demethylase, JMJD3, has relatively high oxygen 
affinity and was not sensitive to hypoxia. Mutagenesis of key residues in UTX’s catalytic domain 
to resemble that of JMJD3 was sufficient to increase oxygen affinity and restore differentiation in 
hypoxia26. It will be critical in the future to perform analogous experiments to manipulate 
sensitivity to fluctuations in TCA cycle metabolites so as to identify primary responders in cell 
fate decisions linked to these metabolites. 
 
1.3 CANCER ASSOCIATED MUTATIONS HIJACK METABOLIC CONTROL OF CELL 
FATE  
The identification of recurrent oncogenic mutations in metabolic enzymes sparked interest 
in the role of metabolites as drivers of cell fate decisions. Mutations in IDH1 and IDH2 lead to 
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accumulation of (D)-2HG, while mutations in SDH components and FH lead to accumulation of 
succinate and fumarate, respectively31,36,37. 2HG, succinate, and fumarate are collectively known 
as oncometabolites, competitively inhibit αKG-dependent dioxygenases, and are often suggested 
to exert similar functions in blocking stem cell differentiation 30,31,33,34,38.  
In vitro differentiation of mesenchymal, hepatic, hematopoietic and neural progenitors are 
all suppressed by expression of mtIDH1/2 or 2HG treatment alone 22,30,39,40. In vivo, expression of 
mtIDH in the brain, bone marrow and liver all lead to expansion of resident progenitor populations 
and suppression of terminal differentiation 39,41,42. SDH-deficient paragangliomas arise in the 
oxygen sensing carotid bodies, a neural crest derived organ, and Sdhd loss is associated with 
carotid body hypertrophy and reduced differentiation 43,44. Together, these studies suggest that 
inhibitory metabolites act by suppressing the competence of stem cells to respond to appropriate 
differentiation stimuli, such that stem cell division is skewed towards self-renewal. 
In classic models of cell fate induction, cellular competence to respond to inductive signals 
for fate changes can be suppressed by direct inhibitors of that signaling pathway. For example, in 
the developing skin spatially restricted expression of Wnt inhibitors leads to distinct fate outcomes 
of Wnt-responsive and non-responsive cells45,46. By analogy, the pervasive observation that 
oncometabolites block differentiation across multiple lineages raises the possibility that αKG 
could be an inductive signal for adult stem cell differentiation. In support of this model, ascorbate, 
which promotes αKG-dependent dioxygenase function, drives hematopoietic stem cell (HSC) 
differentiation and suppresses leukemogenesis47,48. Exogenous αKG also promotes cytokine-
induced HSC differentiation49, and αKG is necessary and sufficient for effector T-cell 
differentiation50,51. Notably, the effects of αKG extend beyond tissues that are prone to 
transformation by oncometabolites. In both intestinal and epidermal stem cells, αKG is sufficient 
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for stem cell differentiation and suppressed tumor initiation and progression14,52. The effects of 
αKG extend to transformed cells: in pancreatic cancer cells, p53 restoration drives αKG-dependent 
differentiation, and αKG alone is sufficient to recapitulate the effects of p5353. When tested in 
these settings, succinate showed little effect except under conditions of αKG accumulation14,53, 
consistent with αKG acting as an inductive signal and its antagonists establishing repressive 
thresholds for cell fate changes. In this manner, mutations in metabolic enzymes that lead to 
accumulation of 2HG, succinate and fumarate may be akin to mutations in key tissue specific 
signaling pathways that normally act to restrain stem cell self-renewal.   
 
1.4 CANCER ASSOCIATED MUTATIONS SUGGEST LINEAGE SPECIFIC EFFECTS 
OF METABOLITES  
 Despite evidence that 2HG, succinate and fumarate act via similar mechanisms, mutations 
that drive accumulation of these oncometabolites occur in tumors of distinct lineages. For example, 
acute myeloid leukemia (AML) and gliomas harbor IDH but not SDH and FH mutations, whereas 
the opposite is true for renal cell carcinoma and neuroendocrine tumors31,54,55. The non-
overlapping patterns of mutations suggest tissue-specific functions of these metabolites, despite 
their similar effects in biochemical assays. Thus, it is critical to understand how metabolites act in 
the context of the particular cohort of lineage specific signals and factors experienced by individual 
cells. Below, I discuss evidence that the response to a metabolite is lineage specific and in 
subsequent sections I review potential mechanisms by which lineage factors and environmental 
inputs might shape the cellular response to individual metabolites. Collectively, these studies raise 
two related but separate points: specific metabolites may be required for particular chromatin 
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changes and cell fate decisions, and different lineages may exhibit distinct responses and 
sensitivities to metabolites.  
The potential for context-specific effects of metabolites has been best studied in 
hematopoiesis, which is fueled by HSCs. Consistent with an oncogenic function for 2HG, 
expression of mtIDH1/2 or treatment with (D)-2HG alone leads to increased proliferation and self-
renewal of HSCs and other hematopoietic progenitors at the expense of proper differentiation in 
vitro and in vivo23,38,41. Accordingly, mtIDH2 cooperates with additional oncogenic hits to drive 
leukemogenesis in mice 56. In contrast, both SDH and FH loss lead to impaired HSC maintenance 
and function. Moreover, FH loss suppressed, rather than supported, leukemic transformation 57,58.  
One possible explanation for disparate effects of IDH, SDH and FH mutations is that SDH 
and FH are components of the core oxidative TCA cycle, whereas IDH1 and IDH2 are not. Thus, 
it may be that HSCs are unable to cope with TCA cycle truncation, which requires distinct 
metabolic adaptations 59. A second potential reason for this discrepancy, however, is the unique 
effects of (D)-2HG versus succinate and fumarate on αKG-dependent dioxygenases. Whereas 
mtIDH1/2 inhibited both TET2-mediated DNA demethylation and JmjC-KDM-mediated histone 
demethylation, FH loss in HSCs only inhibited histone demethylation 38,41,58. Fumarate 
additionally functions to modify reactive cysteine residues, and thus is likely to exert functions 
independent of αKG-dependent dioxygenases 35,60. Altogether, these studies support distinct 
effects of succinate, fumarate and 2HG accumulation on HSC behavior.  
In AML, multiple neomorphic mutations in IDH1 and IDH2 occur, all of which are 
sufficient to induce (D)-2HG and block hematopoietic differentiation 23,38,41. As noted above, 2HG 
accumulation is thought to play a major role in suppressing HSC differentiation by antagonizing 
TET2 function. This notion has been bolstered by the observation that IDH1/2 mutations in AML 
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are mutually exclusive with TET2 mutations, and TET2 loss of function phenocopies mtIDH 
expression 23,38. Even within the hematopoietic lineage, however, IDH mutations may exert distinct 
effects. For example, IDH mutations occur only at R172 of IDH2 in angioimmunoblastic T-cell 
lymphoma (AITL), where they co-occur with TET2 mutations. IDH2 R172 mutants produce 
significantly more 2HG than other mutants, and only IDH2 R172 mutant expression disrupts T-
cell differentiation in mouse models61. These data suggest that 2HG dosage may have cell-type 
specific effects and that the same metabolite can exert distinct effects at different stages of a 
developmental trajectory. Thus, gaining an understanding of how metabolites cooperate with 
lineage specific transcription factors and signaling pathways may provide insight into why 
metabolites exhibit cell-type specific effects.  
 
1.5 METABOLIC INTERACTION WITH LINEAGE SPECIFIC TRANSCRIPTION 
FACTORS  
Studies highlighting the context-specific effects of oncometabolites indicate that 
metabolites will likely regulate cell fate decisions in a tissue-specific manner. Given the abundance 
of literature on the critical role transcription factors (TFs) and cell-type specific enhancer 
landscapes play in establishing and maintaining cell identity, it is likely that effects of metabolites 
will vary according to their ability to interact with lineage specific transcriptional machinery. In 
this section I discuss two potential mechanisms by which metabolites may regulate cell fate 
changes: first, I review evidence that metabolites can directly control TF abundance and 
expression; and second, I review data suggesting that metabolites regulate TF activity by globally 
modulating co-activator function. Since different cell fate changes are likely to rely on distinct TF 
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and co-activator cohorts, these data may provide an explanation for lineage specific effects of 
metabolites.  
Limited evidence suggests that metabolites may act upstream of lineage TFs. In the liver, 
mutant IDH1 expression blunts progenitor differentiation into hepatocytes by silencing the master 
TF HNF4α39. In intestinal tumor organoids, αKG is sufficient to suppress activation of the master 
intestinal stem cell regulator β-catenin and induce differentiation52. Despite these observations and 
correlations with changes in DNA and histone methylation at TF promoters and target gene loci, 
the exact mechanisms by which metabolites affect expression of specific TFs are not well 
understood.   
Appealing mechanisms by which metabolites could act upstream of master lineage 
regulators are via post-transcriptional and post-translational regulation of TF expression. The RNA 
demethylases FTO and ALKBH5, which demethylate N6-methyladenosine (m6A), are αKG-
dependent dioxygenases. m6A destabilizes transcripts and has been found to regulate expression 
of key TFs in embryonic stem cells (ESCs) and HSCs 62–64. Moreover, it was recently shown that 
2HG suppresses FTO activity in leukemia cells, leading to decreased expression of the lineage TF 
CCAAT enhancer binding protein α (C/EBPα), which enforces normal HSC quiescence and 
myeloid differentiation 65–67. In this manner, direct metabolic regulation of key TF expression may 
enable specific cell fate outcomes.  
Metabolites also exert post-translational control over TFs, as exemplified by the dominant 
role of αKG-dependent prolyl hydroxylation in the control of  HIF1α stability 25,33. Studies in 
macrophages recently uncovered the ability of αKG-dependent prolyl hydroxylases to regulate 
other TFs during cell fate decisions. These studies revealed that αKG is necessary for anti-
inflammatory M2 polarization and sufficient to suppress pro-inflammatory M1 polarization. While 
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the effects of αKG on M2 polarization required the H3K27me3-demethylase JMJD3, αKG 
suppressed M1 polarization by inhibiting the master inflammatory TF NFkB via prolyl-
hydroxylase-dependent modification of its activator IKKβ. Accordingly, a hydroxylation-dead 
IKKβ mutant rendered M1 polarization resistant to αKG 68. Thus, exploring post-transcriptional 
and post-translational regulation of TFs by αKG-dependent hydroxylases may identify new layers 
of regulation by which metabolites can induce cell fate changes (Fig. 1.2a).  
Transcription factors can regulate gene expression by recruiting co-activators and/or co-
repressors to target loci 7. Co-activators, including TETs and H3K27me3 demethylases 
JMJD3/UTX, require αKG as a co-substrate, raising the possibility that metabolites function in 
cell fate decisions by regulating TF function via potentiating or suppressing co-activator activity 
(Fig. 1.2b). This model has been best studied in mouse embryonic stem cells (ESCs). ESCs can be 
maintained in vitro in a heterogeneous state of metastable pluripotency or as a homogeneous 
population of cells in the naïve ground state of pluripotency via culture in specific media 
formulations. The naïve ground state of pluripotency is intrinsically associated with an 
accumulation of αKG at the expense of succinate, which is reflected by an increase in the 
αKG/succinate ratio, due to reduced αKG catabolism in the TCA cycle13,29. Notably, 
supplementing metastable ESCs with αKG is sufficient to facilitate TET and UTX/JMJD3-
mediated DNA and histone demethylation, respectively, and increase pluripotent self-renewal29.  
The ground state of pluripotency is characterized by a robust TF network, whose action is 
facilitated in part by recruitment of TET1/2 to key pluripotency loci 69–71. This robust 
transcriptional network enables naive, but not metastable, ESCs to maintain growth and 
pluripotency upon inhibition of the co-activator Brd4, which binds acetylated histones to activate 
transcription and is usually essential for maintenance of gene expression programs72. The ability 
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of pluripotency TFs to confer Brd4 independence and sustain self-renewal is sensitive to metabolic 
perturbations, since glutamine starvation – which depletes αKG – blunts expression of key 
pluripotency genes and ascorbate enhances self-renewal in the presence of Brd4 inhibitors 69. 
Intriguingly, mtIDH AMLs are highly sensitive to Brd4 inhibition 56. Whether or not this 
sensitivity is due to decreased ability of αKG-dependent dioxygenases to function downstream of 
master hematopoietic TFs upon 2HG accumulation remains to be explored but would be consistent 
with the data in ESCs. 
Core pluripotency TFs are known to drive their own expression, creating a positive 
feedback loop, and can remain bound to target genes even upon induction of differentiation 
stimuli73,74. This enables ESCs to revert to pluripotency upon withdrawal of differentiation stimuli 
so long as these key TFs remain chromatin bound 74. Thus, if αKG acts by promoting pluripotency 
TF function, loss of these TFs from chromatin late in differentiation would blunt the effects of 
αKG. Consistently, αKG can only sustain ESC pluripotency when provided early after a 
differentiation stimulus, when expression of pluripotency TFs remains high 75. Differentiation is 
associated with a decrease in αKG that coincides with the loss of pluripotency TFs; conversely, 
overexpression of key pluripotency factors such as NANOG or activated STAT3 are sufficient to 
increase αKG, suggesting that αKG accumulation may be a component of the feed-forward loop 
of the pluripotency network 13,75.  
Notably, αKG doesn’t always enhance ESC self-renewal. In more committed pluripotent 
cells such as human ESCs and mouse post-implantation epiblast ESCs, however, αKG actually 
facilitated differentiation, which was antagonized by succinate 76,77. The differential response to 
αKG may reflect either the more committed state of human and mouse epiblast ESCs or the 
particular differentiation stimuli used in each condition. Alternatively, αKG may exert different 
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outcomes as a result of distinct requirements for self-renewal vs. differentiation in different cell 
states, either due to different cohorts of TFs or different required changes in chromatin to achieve 
a cell state change. Notably, the naïve and more committed, primed states of pluripotency have 
dramatically different levels of DNA methylation 78, and thus may have different sensitivity to 
metabolic perturbations that favor demethylation. Given that αKG can influence both TF 
expression directly and function indirectly, metabolites are likely to play numerous roles in 
particular cell fate decisions, depending on the specific requirements of that cell state.  
Recent evidence suggests that oncometabolites also can act by blunting co-activator action 
at lineage specific genes. For example, during muscle differentiation the master TF MyoD recruits 
H3K9me2/3 demethylases to target loci to promote expression. Accordingly, mtIDH1 expression 
suppresses MyoD-mediated differentiation, which is rescued by genetic inhibition of H3K9 
methyltransferases. Whereas normal myogenic differentiation is accompanied by selective 
hypomethylation of H3K9 at myogenic targets, mtIDH1 expression drives global, apparently non-
selective increases in H3K9me3 79. These results support a model wherein 2HG accumulation in 
myoblasts establishes a global chromatin landscape that is incompatible with differentiation due 
to inhibition of H3K9 demethylases, whereas locus specificity during differentiation is achieved 
by TF recruitment of co-activators. Consistently, work in neural, mesenchymal and hematopoietic 
cells shows that IDH mutations render stem cells unable to appropriately respond to differentiation 
stimuli, although the interaction between master TFs, co-activators and metabolites remain to be 
explored in these settings 23,30,38,40. Thus, the ability of metabolites to regulate specific cell fate 
changes is likely due to the combinatorial effects on lineage specific factor expression and 
function, and gaining a detailed understanding of context-specific effects of metabolites will likely 













Fig. 1.2. Potential mechanisms of metabolic control of cell fate. a, αKG-dependent 
dioxygenases can directly impact expression of key transcription factors (KTFs) both by regulating 
mRNA methylation and protein hydroxylation, both of which trigger target degradation. b, 
Metabolites can regulate TF function by influencing co-activator function, a subset of which are 
αKG-dependent dioxygenases. Transcription factors recruit co-activators such as TETs and KDMs 
to target loci in order to locally remodel chromatin. c, Metabolites can impact enhancer function 
and long range chromatin interactions by controlling CTCF binding to DNA, which is suppressed 
by DNA methylation. αKG enforces TAD architecture in cells by facilitating CTCF binding, 
whereas 2HG, succinate and fumarate disrupt TAD architecture. In the presence of CTCF, a cell-
type specific active enhancer drives expression of your favorite gene-A (YFG-A), whereas YFG-
B is suppressed. Upon loss of CTCF binding, however, TAD boundaries are disrupted and the 






















1.6 METABOLIC CONTROL OF LINEAGE SPECIFIC ENHANCERS  
A key component of cell fate decisions involves TF-mediated establishment and binding 
of cell type specific enhancers 80. Active enhancers are marked by acetylation of H3K27 and can 
be suppressed by H3K27me3 and DNA methylation 81. Accordingly, metabolic regulation of αKG-
dependent dioxygenases can directly regulate enhancers. For example, FH deficient renal cells 
exhibit increased DNA and H3K27 methylation at a putative enhancer for the microRNA cluster 
mIR-200. Fumarate-mediated enhancer methylation suppressed the anti-metastatic miR-200 
cluster, activating the epithelial-mesenchymal transition (EMT). Interestingly, exogenous αKG 
reversed fumarate-induced EMT, suggesting that ongoing αKG-dependent dioxygenase activity 
may be required for maintenance of the epithelial phenotype 82.  
Recent studies profiling three-dimensional chromatin landscapes and the ubiquitously 
expressed transcription factor CCCTC-binding factor (CTCF) have provided additional insights 
into the interactions between metabolites and enhancers. The genome is organized into discrete 
regulatory units called topologically associated domains (TADs), whose boundaries are 
established by CTCF binding 83. Enhancers preferentially drive expression of genes within their 
own TADs; accordingly, CTCF loss increases inter-boundary interactions at the expense of intra-
boundary interactions, thereby modifying enhancer-promoter contacts and altering gene 
expression83. DNA methylation is emerging as a critical barrier to CTCF binding and TAD 
regulation that is susceptible to metabolic perturbation 83. In both mtIDH gliomas and SDH-
deficient gastrointestinal stromal tumors, hypermethylation of CTCF binding sites is associated 
with increased interactions between key receptor tyrosine kinase (RTK) genes and constitutive 
lineage-specific enhancers normally outside of their domains, driving RTK expression. Deletion 
of key CTCF binding sites alone phenocopied the effects of mtIDH or SDH loss on RTK 
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expression 84,85. Similarly, experiments performed in a human ESC model of glioma demonstrated 
that mtIDH suppressed differentiation by disrupting CTCF binding, leading to reduced interaction 
of the SOX2 locus with an active enhancer 86. Collectively, these studies demonstrate the potential 
of oncometabolites to influence enhancer activity towards target genes (Fig. 1.2c). 
Intriguingly, CTCF is ubiquitously expressed, and many of its binding sites are shared 
between different cell types 87. Therefore, metabolic regulation of CTCF per se is not sufficient to 
result in tissue specific effects; rather, the particular enhancer landscape of a cell will play a key 
role determining the transcriptional outcomes of altered CTCF binding. For example, αKG induces 
increases in CTCF binding at overlapping loci in ESCs and T-cells, but cell-type specific changes 
in gene expression. In T-cells, αKG supports effector T-cell differentiation by increasing 
interactions of IL-2 target genes with active T-cell enhancers. Although αKG also increases CTCF 
binding in the vicinity of key ESC genes in T-cells, these genes are not transcriptionally induced 
because they lack active enhancers in T-cells50.  Altogether, these data support a model wherein 
αKG and its inhibitors contribute to cell fate regulation by controlling three-dimensional chromatin 
architecture, but specific cell fate outcomes are driven by the enhancer landscape of a cell. Most 
likely, all of these factors can converge enabling metabolites regulate cell fate changes by co-
regulating chromatin architecture and TF function.  
 
1.7 NUTRIENTS REGULATE αKG-DEPENDENT DIOXYGENASES 
 In vivo cell fate changes do not occur in isolation, but rather in a spatiotemporally defined 
manner that is under the control of a cell’s microenvironmental milieu, or niche3. Many niche 
derived signals can induce changes in intracellular metabolism. For example, growth factor 
signaling acutely increases nutrient uptake, and stromal cells can provide metabolic support to 
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stem cells by directly providing nutrients88,89. Additionally, the nutrients supplied to a tissue may 
also influence cell fate by controlling intracellular metabolite abundance. Stem cells of multiple 
tissues, including those of the blood, brain and skin are in close proximity to the vasculature, 
suggesting that their nutrient microenvironment may be closely regulated via control of blood 
supply and drainage 90–92. Given recent evidence that the extracellular nutrient milieu may vary in 
a tissue-specific manner 16,93, I discuss the possibility that nutrient availability within stem cell 
niches could contribute to cell fate decisions through αKG-dependent dioxygenases (Fig. 1.3).   
Oxygen. How cells adapt to hypoxia has been thoroughly reviewed elsewhere 94, and here 
I highlight how αKG-dependent dioxygenases contribute to the cellular response to changes in 
oxygen availability. While all αKG-dependent dioxygenases consume oxygen, only a subset have 
sufficiently low affinity for oxygen to be limited by physiological levels of hypoxia 26. However, 
hypoxic conditions, which induce intracellular acidification and high intracellular NADH/NAD+ 
favor promiscuous reduction of αKG to (L)-2HG by lactate dehydrogenase and malate 
dehydrogenase 95,96. This rise in (L)-2HG, which inhibits most αKG-dependent dioxygenases more 
potently than (D)-2HG, is necessary and sufficient for hypoxic hypermethylation of histones in 
certain contexts 97. Collectively, these findings suggest that hypoxia may block αKG-dependent 
dioxygenase activity through multiple mechanisms.  
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Fig. 1.3. Niche regulation of αKG-dependent dioxygenases. Summary of potential regulators 
within the stem cell niche of stem cell dioxygenase activity. αKG is largely derived from 
glutamine, whereas serine and valine have been shown to suppress intracellular αKG levels.  
Hypoxia directly antagonizes dioxygenase activity and facilitates production of 2HG from αKG. 
Finally, the role of niche cells in αKG-dependent dioxygenase activity has yet to be explored but 
is a potential regulator, as many stem cells reside in proximity to the vasculature and stromal cells 
may provide nutrients to stem cells and/or compete with stem cells for nutrients within the niche. 
 
 Intriguingly, many stem cells including neural and hematopoietic stem cells reside in 
hypoxic niches and can be regulated by HIF1a signaling 98–103. Notably, malignant ependymomas, 
derived from hypoxic fetal neural precursors, require hypoxia to proliferate due to metabolic 
requirements to maintain histone methylation and acetylation 104. Whether or not metabolic 
responses to hypoxia also contribute to normal stem cell behavior remains an open question. In 
particular, hypoxia-induced 2HG could create a non-permissive environment for differentiation, 
thereby coupling hypoxic niches to homeostatic stem cell self-renewal. While the majority of 
HSCs reside in hypoxic peri-sinusoidal niches, some studies report a small percentage of 
progenitors in well-oxygenated peri-arteriolar regions 105,106. Whether these HSCs are functionally 
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distinct in their ability to differentiate remains to be seen, but an intriguing possibility is that 2HG 
levels would decline upon migration to better perfused niches, enabling differentiation. In this 
model, IDH1/2 mutations would effectively uncouple HSC differentiation from niche regulation 
via constitutive 2HG production. Studying the role of oncometabolites and αKG in tissue stem 
cells experiencing physiological hypoxia will be an interesting area of research in the future.  
Amino acids. In most proliferating cells in vitro, glutamine is the major contributor to the 
carbon backbone of the TCA cycle. Glutamine is first deamidated to glutamate, which is then 
deaminated to αKG via transaminase reactions or glutamate dehydrogenase. Accordingly, 
manipulating extracellular glutamine levels has been shown to regulate TCA cycle metabolites, 
cell fate, and proliferation 21,107. As discussed earlier, reduced catabolism of glutamine-derived 
αKG in the TCA cycle enables naïve mouse ESCs to maintain an elevated αKG/succinate ratio 
and to proliferate in the absence of glutamine 13,29. Accordingly, glutamine has two distinct roles 
in regulating ESC fate. Transient glutamine withdrawal selects for ESCs with enhanced self-
renewal due to death of more committed cells. However, because glutamine is the major source of 
αKG, prolonged glutamine starvation decreases ESC self-renewal. Re-supplementation of 
glutamine after a transient withdrawal therefore enables naïve ESCs to recover expression of key 
pluripotency markers 13.  
 Glutamine is also a key regulator of αKG abundance and cell fate in adult tissues. In 
macrophages, glutamine starvation blunts M2 polarization and favors a pro-inflammatory 
phenotype, which can be reversed by αKG supplementation 68. Similarly, glutamine starvation in 
T-cells prevents effector differentiation, which can be restored via αKG treatment. Glutamine 
starved or (L)-2HG treated T-cells adopt a memory T-cell fate, a subset of which may have stem 
cell properties 50,51,108.  Similarly, glutamine starvation enhances stemness of intestinal organoids 
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harboring pre-malignant oncogenic mutations and increases tumor initiating capacity 52. While 
these studies relied on in vitro glutamine starvation, heterogeneity in glutamine availability may 
also be an important determinant of cell fate in vivo. For example, glutamine deficiency in 
melanoma cores in vivo is sufficient to blunt cancer cell differentiation due to αKG depletion, and 
increasing dietary glutamine is sufficient to increase αKG levels and impair tumorigenesis 109,110. 
Altogether, these data are consistent with glutamine availability creating a permissive environment 
for cell fate determination by enabling αKG accumulation. Thus, anti-cancer therapies aimed at 
suppressing glutamine uptake and catabolism may inadvertently select for the most aggressive 
stem cells in a tumor.  
Conversion of glutamate to αKG is largely accomplished by transaminase enzymes in 
proliferating cells, which reversibly donate the amine nitrogen of glutamate to a ketoacid in order 
to synthesize a non-essential amino acid (NEAA) and αKG 107. Emerging evidence suggests that 
which particular transaminases predominantly contribute to αKG may vary in a tissue-specific 
manner. In IDH wild-type AML, catabolism of the branched chain amino acids (BCAA) valine, 
leucine and isoleucine by branched chain aminotransferase 1 (BCAT1) restricts intracellular αKG 
levels, leading to DNA hypermethylation and HIF1α stabilization. Notably, BCAT1 loss blunts 
AML stem cell growth and induces myeloid differentiation 111. Interestingly, normal HSCs are 
reliant on valine for their maintenance for unknown reasons 112. BCAAs are essential and therefore 
their uptake is required by all cells for protein synthesis, but BCAT activity may be cell-type 
specific 113. It is therefore intriguing to consider that valine supports HSC self-renewal by 
restricting intracellular αKG.  
 In other tissues, serine synthesis represents a notable source of nucleocytosolic αKG 
production via phosphoserine aminotransferase (PSAT1) activity. In breast cancer, 
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hyperactivation of the serine synthesis pathway maintains hypoxic breast cancer cell survival and 
supports αKG production for TCA cycle anaplerosis 114,115. In this thesis, I show that in the murine 
epidermis, in vivo restriction of serine and its immediate downstream metabolite glycine triggers 
de novo serine synthesis activation in epidermal stem cells and accumulation of αKG, which is 
necessary and sufficient to drive stem cell differentiation, H3K27me3 demethylation, and tumor 
suppression 14. Intriguingly, dietary serine and glycine restriction has proven effective in delaying 
tumorigenesis in other models as well, and it will be of interest to understand whether or not αKG-
dependent stem cell differentiation plays a role in these systems116,117. Collectively, these studies 
demonstrate that dietary manipulation of extracellular nutrient availability is sufficient to regulate 
stem cell fate in part by controlling intracellular αKG levels.  
 
1.8. CONCLUSIONS 
Proper development and adult tissue function requires careful control over cell fate 
programs. Collectively, the above studies suggest that metabolites act as both inductive signals 
and regulators of competence during cell fate determination, and thus disruption of tissue specific 
pathways that maintain TCA cycle homeostasis promotes pathology, most notably by enforcing 
progenitor self-renewal and driving tumorigenesis.  Metabolite abundances—determined by 
environmental nutrient availability and cell-type specific genetic programs—can collaborate 
closely with lineage specific transcriptional programs to regulate cell fate. Evidence across 
multiple tissues suggest a model wherein αKG acts as an inducer of cell fate changes, while 
succinate, fumarate and 2HG largely restrict competence to appropriately execute cell fate 
programs. Accordingly, nutrients that fuel intracellular αKG pools create permissive environments 
for cell fate decisions, and mutations that drive oncometabolite accumulation prevent αKG-
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mediated cell decisions. The roles of specific oncometabolites in lineage-specific cancers warrants 
investigation into the role of αKG during development and differentiation of their normal tissue 
counterparts. More broadly, whether the tissue specific profiles of cancer-associated mutations in 
chromatin modifying enzymes such as TETs and DNA and histone methyltransferases likewise 
predict metabolite-responsive nodes co-opted by tumors will be an important area of future 
investigation.  
Future studies should be aimed at better dissecting the roles of specific dioxygenases in 
responses to metabolites and the cell-type specific roles of metabolites within native tissue 
microenvironments. In particular, whether or not the availability of endogenous nutrients 
fluctuates sufficiently to modulate intracellular metabolite abundances and cell fate outcomes 
remains to be explored. Finally, although many studies support the role of metabolic changes 
regulating cell fate decisions, relatively few studies address whether or not basal metabolism 
supports the maintenance of cell-type specific gene expression outputs and accordingly, the 
maintenance of cell identity. For example, do transcription factors require a basal level of αKG to 
sustain cell identity once a cell’s chromatin landscape is established, or do changes in αKG pools 
only enable dynamic reprogramming of gene expression? Improved technologies to enable 
measurement of extracellular, subcellular and cell-type specific metabolite abundances in vivo, 
coupled with genetic experiments to modulate dioxygenase sensitivity to metabolites, will 
facilitate our ability to gain a deeper understanding of the physiological and pathological roles of 
metabolites in controlling cell fate.  
In this thesis I explore the role of nutrient availability and αKG-dependent dioxygenases 
in epithelial stem cells of the skin epidermis. The skin houses an abundant reservoir of stem cells 
which maintain distinct tissues within the organ. These include the stem cells of the interfollicular 
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epidermis (IFE), which maintain the skin barrier that is essential for maintaining organismal water 
and electrolyte balance while protecting us from external infectious and noxious agents, and those 
of the hair follicle (HF) which regenerate the hair coat of mammals. 
 Epithelial stem cells of the skin give rise to malignancies include squamous cell 
carcinomas (SCCs) and basal cell carcinomas (BCCs) and are additionally required for wound 
repair3. While many foundational studies have identified the core signaling and transcriptional 
machinery involved in skin stem cell homeostasis and pathology118, the metabolic determinants of 
stem cell behavior in the skin remain largely unexplored. In particular, while recent studies have 
highlighted the importance of metabolic pathways such as glucose uptake and glycolysis in 
supporting skin stem cell proliferation119,120, little is known about whether or not particular 
metabolites regulate stem cell identity or the balance of fate decisions in the skin. I explore the 
role of nutrient availability in regulating stem cell fate during SCC initiation as well as epidermal 
growth and differentiation. These studies establish extracellular nutrient availability as 


















 Stem cells (SCs) maintain tissue homeostasis by balancing self-renewal and 
differentiation3. With age, SCs can acquire cancer-associated mutations and clonally expand in the 
context of a grossly normal tissue121–125. How SCs contend with pre-malignant oncogenic 
mutations, and the mechanisms that ultimately drive a subset of progenitors to initiate neoplasms, 
remain largely unknown. The answers become increasingly important given evidence that SCs, 
but not terminally differentiated cells, are a major root of malignancy126–129, and that driving SC 
differentiation is a potent tumor suppressive mechanism130–133. Thus, identifying factors that 
regulate oncogenic SC fate is critical to delineating the mechanisms that drive tumor initiation.  
The innermost (basal) layer of mammalian epidermis houses an abundant reservoir of SCs 
responsible for maintaining the skin barrier. Acquisition of oncogenic mutations predisposes 
epidermal stem cells (EpdSCs) to initiate benign tumors, which progress to squamous cell 
carcinomas (SCCs), among the most common cancers worldwide3. As such, the epidermis is an 
excellent model to understand the mechanisms regulating pre-malignant SC behavior.  
During SCC pre-malignancy, epigenetic and/or genetic mechanisms lead to induction of 
the transcription factor SOX2, which is necessary for tumor initiation and progression134–136. 
Ectopic activation of SOX2 in EpdSCs induces a stress response involving global protein synthesis 
repression and selective translation of oncogenic transcripts135,137. Since protein synthesis is 
intimately tied to amino acid availability138, this prompts the intriguing but unexplored hypothesis 
that SCs may adapt to oncogenic stress by altering their metabolism.   
Increasing evidence suggests that metabolites can regulate SC proliferation, self-renewal 
and differentiation13,21,29,119,139. Additionally, metabolic reprogramming supports bioenergetic and 
anabolic reactions that are necessary for proliferation21, rendering tumor progression sensitive to 
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nutrient availability116,117,140. However, it remains unknown whether oncogenic lesions rewire 
endogenous metabolic programs in SCs, and if so, how this contributes to tumor initiation. Here, 
I assessed the consequences of oncogenic stress to EpdSC metabolism and discovered that 
metabolic reprogramming suppresses differentiation programs that otherwise antagonize 
tumorigenesis. These results hold promise for therapeutic avenues targeting oncogenic SCs. 
 
2.2. RESULTS 
2.2.1. Pre-malignant SC growth is dependent upon extracellular serine. 
Sustained SOX2 expression in EpdSCs induced pre-tumorigenic lesions marked by 
hyperproliferation, expansion of K14+ progenitors, and induction of the tumor stem cell (tSC) 
marker CD44 (Fig 2.1a). To explore the metabolism of pre-malignant EpdSCs prior to the onset 
of hyperproliferation, I crossed R26-LSL-Sox2-IRES-eGFPfl/fl and Krt14-Cre+/wt mice to generate 
littermate wild-type (WT) and SOX2+ animals, where Sox2 was induced developmentally in K14+ 
epidermal progenitors135,141 (Fig. 2.1b). At postnatal day 4 (P4) and in primary culture, SOX2+ and 
WT EpdSCs proliferated comparably (Fig. 2.1b,c), enabling us to identify metabolic changes 




Figure 2.1. SOX2 induction as a model of pre-malignancy in epidermal stem cells. a, 
Representative immunofluorescence of progenitor markers a6 and K14, tumor SC markers CD44 
and SOX2, and EdU incorporation in P65 WT and SOX2+ mice two weeks after tamoxifen 
administration. b, EdU incorporation into integrin-a6+ EpdSCs in P4 WT and SOX2+ mice. c, 
Growth of independently derived WT-1,2,3 and SOX2+-1,2,3 EpdSC cultures. 
  
Like SCC-SCs, SOX2+ EpdSCs decrease protein synthesis relative to WT EpdSCs135,137. 
Since amino acids provide the majority of cellular biomass142, I asked whether pre-malignant 
EpdSCs have altered amino acid requirements. Gas chromatography-mass spectrometry (GC-MS) 
of medium from primary cultures revealed that essential amino acids were consumed at similar 
rates between WT and SOX2+ EpdSCs (Fig. 2.2a). Of the non-essential amino acids, only 
glutamine, tyrosine and serine were appreciably consumed, consistent with reports in cancer 
cells142. Of these, only serine was differentially consumed (Fig. 2.2a,b).  
Unexpectedly, despite reduced translation135, SOX2+ cells consumed more serine than WT 
cells. Glycine, which can be interconverted with serine by serine hydroxymethyltransferases 
(SHMT1/2), was not appreciably consumed (Fig. 2.2b). These results suggested that SOX2+ 
progenitors deviated from WT EpdSCs in serine metabolism. Culturing EpdSCs with uniformly 
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13C-labeled serine confirmed that SOX2+ cells derived a larger portion of intracellular serine from 
extracellular sources (Fig. 2.2c).  
I next analyzed the consequences of withdrawing extracellular serine from the culture 
medium. To minimize possible confounding effects arising from converting glycine to serine under 
starvation conditions, I also removed glycine. When deprived of exogenous serine and glycine 
(Ser/Gly), SOX2+ cells did not maintain intracellular serine pools as well as WT EpdSCs and their 
proliferation halted (Fig. 2.2d,e). By contrast, WT EpdSCs proliferated normally. Ser/Gly 
dependence was independent of the oncogene used to induce pre-malignancy, as HRasG12V-
expressing EpdSCs also required exogenous Ser/Gly to proliferate (Fig. 2.2f). These data indicate 
that oncogenic EpdSCs rely upon exogenous Ser/Gly to sustain proliferation.  
The proliferative block of pre-malignant EpdSCs upon Ser/Gly deprivation was surprising, 
given that both can be synthesized de novo143. To determine whether synthesis of one or both 
amino acids was defective in SOX2+ cells, I depleted each individually. Consistent with minimal 
net consumption of glycine (Fig. 2.2b), glycine deprivation did not affect proliferation. By 
contrast, serine starvation alone inhibited SOX2+ proliferation comparably to combined Ser/Gly 
deprivation (Fig. 2.2g). Thus, pre-malignant EpdSCs are functional serine auxotrophs that rely 
upon obtaining serine from extracellular sources to proliferate. To avoid potential confounding 




Fig 2.2. Pre-malignant EpdSCs are serine auxotrophs. a, b, Gas chromatography-mass 
spectrometry (GC-MS) of conditioned medium relative to control medium NEAA indicates non-
essential amino acids that are consumed. c, 4 hour fractional labeling of intracellular serine from 
[U-13C]serine. d, GC-MS of intracellular serine pools following 16 hours of ser/gly starvation.  e, 
f, Growth during 48 hours of ser/gly starvation. g, Growth during 48 hours in indicated medium. 
 
 
In addition to extracellular consumption, cells can derive serine either from SHMT1/2, or 
from the serine synthesis pathway (SSP), wherein glucose-derived 3-phosphoglycerate (3PG) is 
converted to serine through the sequential enzymes phosphoglycerate dehydrogenase (PHGDH), 
phosphoserine transaminase (PSAT1) and phosphoserine phosphatase (PSPH) (Fig. 2.3a). SOX2+ 
and WT cells exhibited comparable SHMT1/2 expression and Ser/Gly interconversion (Fig. 
2.3b,c). Similarly, SOX2+ cells exhibited no defect in SSP enzyme expression upon Ser/Gly 
deprivation. However, labeling with [U-13C]glucose revealed reduced glucose-derived serine 
synthesis in SOX2+ EpdSCs (Fig. 2.3d). Upon Ser/Gly starvation, WT cells derived the majority 
of their intracellular serine from glucose, while SOX2+ cells failed to do so (Fig. 2.3e). Thus, pre-




Fig. 2.3. Pre-malignant EpdSCs suppress glucose-derived serine synthesis. a,  Schematic of 
intracellular serine sources. b, Western blot for enzymes that catalyze serine synthesis from either 
glucose or glycine following 24 hours of ser/gly starvation. c, 4 hour labeling of serine from 
glycine (left) or glycine from serine (right). d, 4 hour fractional labeling of serine from glucose. e, 
4 hour labeling of serine from glucose following 16 hours of ser/gly starvation. 
 
2.2.2 Limited cytosolic NAD+ regeneration drives serine auxotrophy  
 I next assessed why SOX2+ cells did not employ the SSP. Downstream of the serine 
precursor 3PG, the glycolytic end-product pyruvate can either be shunted to lactate or enter 
mitochondria to fuel the tricarboxylic acid (TCA) cycle. Pyruvate enters the TCA cycle either 
through pyruvate dehydrogenase (PDH) or pyruvate carboxylase (PC) to fuel citrate production 
(Fig. 2.4a).  
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Isotope tracing revealed that SOX2+ cells increased glucose-derived citrate synthesis 
through both PDH and PC (Fig. 2.4b), indicating that pre-malignant EpdSCs were not generally 
defective in glucose metabolism. SOX2+ cells demonstrated increased expression of pyruvate 
carboxylase (Pcx) and pyruvate dehydrogenase E1b (Pdhb) transcripts, suggesting a coordinated 
program favoring mitochondrial pyruvate consumption (Fig. 2.4c). I therefore asked whether 
increasing mitochondrial pyruvate metabolism conferred serine auxotrophy. Increasing pyruvate 
oxidation in WT EpdSCs with dichloroacetate (DCA)144 induced serine auxotrophy (Fig. 2.4d). 
Conversely, blocking mitochondrial pyruvate import using UK-5099145 conferred resistance to 
serine starvation (Fig. 2.4e). These results suggest that elevated mitochondrial pyruvate utilization 





Fig. 2.4. Glucose oxidation drives serine auxotrophy. a, Schematic of glucose metabolism in 
glycolysis and the TCA cycle as well as associated inhibitors. b, 4 hour fractional labeling of citrate 
isotopologues from glucose. m+0 represents citrate that was not labeled by glucose, m+2 and m+3 
represent PDH and PC derived citrate, respectively. Higher order (m+4, m+5, m+6) represent 
subsequent turns around the TCA cycle. c, qPCR for key pyruvate fate enzymes. d-e, Cell count 
following 48 hours of culture in indicated conditions. f, Mechanisms of action of AKB. g, Growth 
of cells during 48 hours of culture in indicated conditions. h, Cell count following 48 hours of 
culture in indicated conditions. 
  
Once imported into mitochondria, pyruvate is no longer a substrate for cytosolic lactate 
dehydrogenase, which reduces pyruvate to lactate to regenerate oxidized NAD+ required for 
glycolysis. As NAD+ is also a cofactor for the rate-limiting SSP enzyme PHGDH146, I 
hypothesized that enhanced mitochondrial pyruvate metabolism of SOX2+ cells limits cytosolic 
NAD+ regeneration, thereby impairing the SSP. Consistent with this hypothesis, a-ketobutyrate 
(AKB), an alternative LDH substrate that enables NAD+ regeneration147 rescued serine 
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auxotrophy in both SOX2+ and DCA-exposed WT cells (Fig. 2.4f-h). Furthermore, the 
pyruvate/lactate ratio, which varies in concert specifically with the cytosolic NAD+/NADH 
ratio148,149, was lower in SOX2+ cells compared to WT cells (Fig. 2.5a,b). Supplementing pyruvate 
to increase the NAD+/NADH ratio147,150 supported increased lactate secretion and rescued serine 
auxotrophy in SOX2+ cells (Fig. 2.5c-e). Conversely, lowering the NAD+/NADH ratio with lactate 
supplementation induced auxotrophy in WT EpdSCs (Fig. 2.5e).  
Genetic interventions to manipulate the NAD+/NADH ratio produced similar results. 
Expression of LbNOX, a bacterial NADH oxidase148, increased the whole-cell NAD+/NADH 
ratio,  increased [U-13C]glucose labeling of serine, and rescued serine auxotrophy of both SOX2+ 
cells and lactate-treated WT cells (Fig. 2.5f-j). Collectively, these findings indicate that cytosolic 
NAD+ regeneration controls serine biosynthesis in EpdSCs.  
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Fig. 2.5 Cytosolic NAD+ Regeneration Dictates Serine Auxotrophy. a, Schematic of pyruvate 
mechanism of action. b, GC-MS quantifaction of the pyruvate/lactate ratio. c, Lactate secretion 
during 24 hours of culture in indicated medium. d, Intracellular serine pools in SOX2+ cells 
following 16 hours in indicated medium. e, Growth during 48 hours of culture in indicated 
medium. f, Mechanism of action of LbNOX. g, Immunofluorescence validating expression of 
LbNOX. h, Quantification of whole cell NAD+/NADH ratio. i, 4 hour fractional labeling of serine 
in SOX2+ cells following 16 hours of ser/gly starvation. j, Growth during 48 hours of culture in 
indicated medium. 
 
2.2.3. Serine restriction induces differentiation of wild-type EpdSCs 
My findings thus far demonstrate that serine auxotrophy distinguishes pre-malignant 
EpdSCs from their normal counterparts. To understand how serine availability affects EpdSC 
function in vivo, I assessed the effects of dietary Ser/Gly withdrawal116,117 on EpdSC growth and 
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differentiation, which must be balanced to maintain homeostasis. I placed pregnant mice on a 
Ser/Gly-free diet (Fig. 2.6a) and analyzed littermate WT and SOX2+ animals at P0. The diet neither 
induced apoptosis in either genotype, nor affected WT EpdSC proliferation; in contrast, Ser/Gly 
restriction impaired SOX2+ EpdSC proliferation (Fig. 2.6b,c). This effect was likely cell 
autonomous, as culturing EpdSCs with low levels of Ser/Gly to mimic dietary restriction 
specifically slowed growth of SOX2+ EpdSCs (Fig. 2.6d). Reduced proliferation of SOX2+ 
EpdSCs in low Ser/Gly conditions was accompanied by a failure to induce the SSP and sustain 
intracellular serine pools (Fig. 2.6e,f). Similar to my in vitro findings, SOX2+ EpdSC proliferation 
in vivo was rescued by enhancing NAD+ regeneration via in utero transduction of epidermal 





Fig. 2.6 Pre-malignant EpdSCs are in vivo serine auxotrophs. a, Serum serine and glycine 
levels of female mice maintained on a control or ser/gly free diet for 2 weeks. b, EdU incorporation 
in P0 mice on a control or ser/gly free diet. c, Immunofluorescence of cleaved caspase 3 in P0 
mice on a control or ser/gly free diet. d-f, In vitro growth (d), intracellular serine pools (e) and 4 
hr fractional labeling of serine from glucose (f) upon 50% reduction of extracellular ser/gly levels. 
g, Schematic (left) and analysis (right) of EdU incorporation in EpdSCs of mice transduced with 
LbNOX, comparing transduced and untransduced EpdSC proliferation in the same mice. 
 
Notably, despite maintaining proliferation (Fig. 2.6), WT epidermis on a Ser/Gly-free diet 
displayed marked thickening of the differentiating layers, typified by expression of Involucrin and 
Keratin-10 (K10) (Fig. 2.7a). Epidermal differentiation is driven by asymmetric cell divisions of 
basal stem cells, in which the division axis of EpdSCs is perpendicular to the basement membrane, 
such that one daughter cell leaves the basal layer to generate a suprabasal cell committed to 
terminal differentiation152. Consistent with increased differentiation, epidermal thickening in WT 
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mice on a ser/gly free diet was accompanied by an increase in EpdSCs dividing perpendicularly to 
the basement membrane (Fig. 2.7b). To directly assess whether extracellular Ser/Gly starvation 
prompted EpdSCs to differentiate prematurely, I utilized a transgenic reporter mouse wherein the 
Krt10 promoter drives H2B-mRFP, thereby marking induction of a terminal differentiation 
program153. Strikingly, Ser/Gly restriction significantly increased the proportion of prematurely-
differentiated Krt10-H2B-mRFP+ EpdSCs (Fig. 2.7c). By contrast, SOX2+ EpdSCs maintained 
planar cell divisions and showed no increase in differentiation (Fig. 2.7b,c).  
To determine whether the effect of Ser/Gly depletion on differentiation was cell-
autonomous, I measured SC (Krt14 and Krt5) and differentiation (Lor and Flg) gene expression in 
vitro. Consistent with our in vivo results, Ser/Gly depletion repressed Krt14/K5 and increased 
Lor/Flg expression specifically in WT EpdSCs (Fig. 2.7d). Partial Ser/Gly restriction and serine 
starvation alone yielded similar results (Fig. 2.7e,f).  Collectively, these data suggest that Ser/Gly 
availability regulates the balance between EpdSC growth and differentiation, and that oncogenic 



















Fig 2.7 Serine starvation drives WT EpdSC differentiation. a, Thickness of terminally 
differentiated cell layers of P0 mice. b, Representative classes (left) and quantification (right) of 
cell division angles of P0 mice based on the angle of the midbody marker Survivin relative to the 
basement membrane. SB = suprabasal. c, Quantification of the differentiation reporter Krt10-H2B-
mRFP in P0 mice. d, qPCR of key stem cell and differentiation genes following 24 hours of ser/gly 
starvation in vitro. e-f, Immunofluorescence (e) and quantification (f) of the stem cell marker K14 
following 24 hours of culture in indicated condition. g, Immunofluorescence and quantification of 










2.2.4. De novo serine synthesis in EpdSCs promotes a-ketoglutarate-dependent 
differentiation 
A priori, differentiation could be due to either serine depletion per se or induction of the 
SSP via one of its byproducts, NADH or a-ketoglutarate (aKG) (Fig. 2.8a). To uncouple these 
possibilities, I knocked down Phgdh, the first SSP enzyme. Phgdh suppression blocked precocious 
differentiation induced by serine restriction, suggesting that SSP flux, rather than serine depletion, 
drives epidermal differentiation (Fig. 2.8b-e).   
I next asked which byproduct of the SSP promoted precocious differentiation. NADH 
seemed unlikely, as interventions that favor NADH oxidation (either AKB or UK5099), promoted, 
rather than inhibited, differentiation (Fig. 2.8f). By contrast, exogenous cell-permeable aKG was 
sufficient to induce differentiation in both WT and SOX2+ EpdSCs (Fig. 2.9a). Moreover, aKG 
restored differentiation in Phgdh-deficient WT EpdSCs, underscoring its ability to trigger the 
consequences of SSP activation (Fig. 2.8d,e).  
Indeed, Ser/Gly starvation of WT EpdSCs led to accumulation of aKG (Fig. 2.9b). 
Importantly, Phgdh silencing blunted aKG accumulation following Ser/Gly restriction (Fig. 2.9c). 
Many reactions can generate aKG from glutamine107. Based on calculations of serine and 
glutamine uptake in WT EpdSCs, I estimated that approximately 10% of consumed glutamine is 




Fig 2.8 Glucose-derived serine synthesis drives αKG dependent differentiation. a, Schematic 
of serine biosynthesis and its by-products. b, Western blot validating knockdown of PHGDH in 
WT EpdSCs expressing either shScramble or shPhgdh hairpins. shPhgdh-1 and shPhgdh-2.2 were 
used for subsequent experiments. c, Validation of shPhgdh lines via proliferation (left) and GC-
MS of intracellular serine pools (right) upon ser/gly starvation. d, Immunofluorescence (top) and 
quantification (bottom) of the stem cell marker K14 cultured in indicated conditions for 24 hours. 
e, Immunofluorescence (top) and quantification (bottom) of the differentiation marker Involucrin 
in indicated conditions for 24 hours. f, Quantification of Involucrin staining in WT (top) or SOX2+ 




Fig 2.9 αKG is necessary and sufficient for ser/gly starvation induced differentiation. a, 
Immunofluorescence of K14 expression in cells cultured with dimethyl (DM)-αKG for 24 hours. 
b-c, GC-MS of intracellular αKG following 16 hours of culture. d-e, Immunofluorescence and 
analysis of K14 (d) or Involucrin (e) in cells cultured with 1 mM of the one carbon donor formate, 
4 mM DM-αKG, or 4 mM DM-succinate for 24 hours. 
 
 
Interestingly, aKG also affected SOX2+ EpdSCs (Fig. 2.9a), indicating that they are not 
generally defective for differentiation. SOX2+ EpdSCs exhibited reduced levels of aKG under 
both control and -Ser/Gly conditions (Fig. 2.9b), consistent with impaired SSP activity. Therefore, 
I asked whether rescuing aKG levels in these cells could restore differentiation. Indeed, aKG 
reversed the differentiation block of Ser/Gly-starved SOX2+ EpdSCs (Fig. 2.9d,e). The ability of 
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aKG to restore differentiation was not merely due to its role as an anaplerotic substrate for the 
TCA cycle downstream of the SSP154, since cell-permeable succinate, another TCA cycle 
intermediated, did not induce differentiation (Fig. 2.9d,e).  
In addition to serving as a substrate for the TCA cycle, aKG is also a co-substrate for a 
large family of dioxygenases that consume aKG and produce succinate as part of their reaction 
cycle8. Succinate, a competitive inhibitor of these enzymes8, was sufficient to block differentiation 
induced by Ser/Gly deprivation (Fig. 2.9d,e). Therefore, I hypothesized that Ser/Gly deprivation 
induced differentiation by activating aKG-dependent dioxygenases. Metabolic regulation of 
aKG-dependent dioxygenases, including the Jumonji-domain family of histone demethylases, has 
been implicated in chromatin regulation and cell fate decisions8,21. In the skin, trimethylation of 
histone 3 lysine 27 (H3K27me3) represses terminal differentiation gene expression. Accordingly, 
EpdSC differentiation is accelerated by conditional loss of Ezh2, an H3K27 methyltransferase, and 
inhibited by loss of the aKG-dependent H3K27me3 demethylase JMJD3155,156.  
Culturing EpdSCs with cell-permeable aKG revealed that H3K27me3 levels are sensitive 
to intracellular aKG levels (Fig. 2.10a). I therefore posited that serine biosynthesis might favor 
aKG-dependent H3K27me3 demethylation, and hence differentiation. Indeed when WT EpdSCs 
were starved for Ser/Gly or serine alone, H3K27me3 levels decreased (Fig. 2.10b-e). H3K27me3 





















Fig 2.10 Serine synthesis drives αKG-dependent histone demethylation. a, H3K27me3 levels 
in cells cultured with 4mM DM-αKG for 24 hours. b, H3K27me3 levels in EpdSCs of P0 mice. c-
d, H3K27me3 levels in cells cultured for 24 hours in the indicated medium. e, H3K27me3 levels 
in shScramble or shPhgdh WT EpdSCs cultured in the indicated medium with or without 4 mM 
DM-αKG for 24 hours. f, H3K27me3 levels in cells cultured in indicated medium with or without 











To directly test the role of H3K27me3 in differentiation induced by Ser/Gly starvation, I 
utilized inhibitors against JMJD3 (GSK-J4) and EZH2 (GSK-343) to block H3K27me3 
demethlyation or methylation, respectively. GSK-J4 prevented H3K27me3 loss and differentiation 
induced by Ser/Gly starvation in WT EpdSCs. Conversely, GSK-343 suppressed H3K27me3 in 
both WT and SOX2+ EpdSCs and promoted differentiation (Fig. 2.11). 
Ser/Gly starvation can exert pleiotropic cellular effects, including depletion of one-carbon 
units that contribute to methylation reactions157 and increased oxidative stress that can drive 
epidermal differentiation117,158. However, one-carbon units did not appear to be limiting, since 
supplying exogenous formate did not rescue H3K27me3 or differentiation (Fig. 2.9e,f, 2.10f). 
Likewise, while antioxidants blocked differentiation, consistent with known roles of ROS in 
differentiation158, they neither affected H3K27me3 nor protected against differentiation upon 
EZH2 inhibition (Fig. 2.11). In contrast, cell-permeable aKG promoted H3K27me3 demethylation 
and differentiation in SOX2+ cells, and cell-permeable succinate suppressed differentiation and 
























Fig 2.11 Ser/Gly induced differentiation is driven by H3K27me3 demethylation. a, b, 
Immunofluorescence (a) and quantification (b) of H3K27me3 and K14 in cells cultured in 
indicated medium for 24 hours with the antioxidants esterified reduced glutathione (eGSH) or the 
vitamin E analog Trolox, the EZH2 inhibitor GSK343 or the JMJD3/UTX inhibitor GSKJ4. c, d, 
Immunuofluorescence (c) and quantification (d) of H3K27me3 and K14 in cells cultured for 24 








Taken together, our data suggest that endogenous serine synthesis poises EpdSCs to 
differentiate by facilitating H3K27me3 demethylation, although additional aKG-dependent 
dioxygenases may contribute to epidermal differentiation. Moreover, SSP suppression enables pre-
malignant EpdSCs to escape differentiation and enforce self-renewal. 
 
2.2.5. Ser/Gly starvation impairs tumor initiation and growth 
 The finding that Ser/Gly starvation induced differentiation led us to posit that Ser/Gly 
deprivation might impair tumor initiation. To investigate this possibility, I placed mice on a 
Ser/Gly-free diet prior to administration of a classical chemical carcinogenesis protocol, in which 
mice are administered a single dose of 7,12-dimethylbenz[a]anthracene (DMBA) followed by 
twice weekly 12-O-tetradecanoylphorbol-13-acetate (TPA), that leads to initiation of EpdSC-
derived benign papillomas and malignant SCCs159 (Fig. 2.12a). Compared to a control diet, 
Ser/Gly starvation significantly impaired tumor initiation and reduced tumor burden (Fig. 2.12b). 
Similar results were obtained upon orthotopic injection of established SCCs into 
immunocompromised (Nude) mice (Fig. 2.12c).  
Tumor growth under dietary Ser/Gly starvation requires enhanced SSP activity17,116. Based 
upon our data, I hypothesized that SSP activation might also  
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Fig 2.12 Dietary ser/gly restriction impairs tumor initiation and growth. a, Schematic of 
DMBA/TPA model of SCC initiation. b, Tumor free survival curve (left), tumor burden (center) 
and representative mice (right) in DMBA/TPA treated mice. c, Tumor growth of established SCCs 
injected intradermally. d-e, H3K27me3 levels in DMBA/TPA (d) and established SCC allografts 
(e). f-g, K14 and K10 staining (f) and quantification (g) in DMBA/TPA induced tumors. h, K10 
staining in SCC allografts grown in mice treated with GSK-J4. 
 
represent a liability for SCCs by driving differentiation. Indeed, tumors that formed under the 
selective pressure of Ser/Gly restriction exhibited reduced H3K27me3 and enhanced 
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differentiation, typified by reduced K14 and increased K10 staining, relative to controls (Fig. 
2.12d-g). Pharmacologically inhibiting aKG-dependent H3K27me3 demethylases160 prevented 
starvation-induced differentiation (Fig 2.12g).  
 
Ser/Gly starvation also induced differentiation, H3K27me3 loss, and growth suppression 
in xenografts of human A431 and SCC9 lines (2.13a-f). Finally, analysis of 139 different cutaneous 
and head and neck human SCCs revealed that H3K27me3 levels correlated with SCC grade (Fig. 
2.13g). Thus, my findings identify a strong link between Ser/Gly availability, H3K27me3 























Fig 2.13 Human SCCs are sensitive to ser/gly restriction. a-c, K14/K10 staining (a), 
H3K27me3 staining (b) and growth (c) in A431 SCC xenografts. d-f, K14/K10 staining (d), 
H3K27me3 staining (e), and growth (f) in SCC9 SCC xenografts. g, Correlation of H3K27me3 







2.2.6. Glucose-derived serine synthesis suppresses tumorigenesis and stemness 
To determine whether the anti-tumor effects of Ser/Gly starvation are due to Ser/Gly 
starvation or SSP activation, I silenced Phgdh in SCCs (Fig. 2.14a,b). In vivo, Phgdh silencing 
prevented H3K27me3 loss upon Ser/Gly starvation (Fig. 2.14c). Consistent with driving 
differentiation, Ser/Gly starvation induced tSC depletion, as reflected by loss of cells expressing 
the tSC markers CD44 and SOX2. Silencing Phgdh expanded the tSC pool and prevented tSC loss 
upon dietary Ser/Gly starvation (Fig. 2.14d,e). Critically, SCC differentiation required an intact 
serine synthesis pathway, since Phgdh silencing blocked diet-induced differentiation, as assessed 
by K14/K10 staining (Fig. 2.14f,g).  
These findings suggested that, in contrast to previous reports on melanoma and breast 
cancer154,161, cell-autonomous SSP activation acts as a tumor suppressor in SCCs by driving SC 
depletion. Consistent with tSC expansion, shPhgdh SCCs grew more rapidly than shScramble 
SCCs under normal growth conditions in vivo (Fig. 2.15a). Importantly, I could abrogate this 
advantage by putting shPhgdh SCCs on a Ser/Gly-free diet, which suppressed shPhgdh SCC 
proliferation (Fig 2.15b,c). Phgdh ablation using CRISPR-Cas9 likewise enhanced tumor growth 
(Fig 2.15d-f). Together, these results underscore the advantage that SCC-SCs gain by silencing 




Fig 2.14 Glucose-derived serine synthesis suppresses SCC stem cell maintenance. a, Western 
blot (left) and growth during 48 hours of ser/gly starvation (right) of shPhgdh mouse SCC lines. 
b, Immunofluorescence of H3K27me3 levels in shPhgdh orthotopic allografts. c-d, 
Immunofluorescence of the stem cell markers CD44 (c) and SOX2 (d) in shPhgdh orthotopic 























Fig 2.15. Glucose derived serine synthesis suppresses tumorigenesis when extracellular 
serine is available. a, Growth of shPhgdh orthotopic allografts on a control diet. b-c, 
Immunofluorescence (b) and analysis (c) of Ki67 staining, a marker of proliferation, in shPhgdh 
allografts under control and ser/gly free diet conditions. d, Growth of shPhgdh allografts under 
control and ser/gly free diet conditions. e-f, validation of PHGDH KO lines. sgPhgdh lines A1 and 
sgPhgdh C6 were used for subsequent experiments and are referred to as sgPhgdh-1 and sgPhgdh-
6, respectively. g, Growth of sgPhgdh orthotopic allografts. 
 






2.2.7. αKG drives tumor suppression and differentiation in SCCs 
Our data suggest that by inducing the SSP, the consequential production of aKG can bias 
tSCs to differentiation and thereby suppress tumorigenesis. To directly test this model, I 
manipulated intracellular aKG and succinate by engineering SCC cells to silence either 
oxoglutarate dehydrogenase (Ogdh) which consumes aKG, or succinate dehydrogenase A (Sdha), 
which consumes succinate (Fig. 2.16a)53. As expected, intracellular aKG was increased in shOgdh 
lines while succinate was increased upon Sdha silencing (Fig. 2.16b).  
While each hairpin reduced tumor growth on a normal diet, they had opposing effects upon 
Ser/Gly restriction (Fig. 2.16c). OGDH loss hampered SCC growth and was sufficient to drive 
H3K27me3 loss and tumor differentiation, as assessed by K14/K10 staining, even on a normal diet 
(Fig. 2.16d-f). This was not due to TCA cycle disruption, as SDHA loss failed to induce 
differentiation in control mice (Fig. 2.20e,f). Rather, SDHA silencing prevented both H3K27me3 
loss and differentiation upon Ser/Gly restriction (Fig. 2.16d-f). As a result, shSdha tumors 
sustained growth in the absence of dietary Ser/Gly (Fig. 2.16c). Collectively, these findings are 
consistent with Ser/Gly starvation inducing activation of aKG-dependent dioxygenases that 



















Fig 2.16. αKG is necessary and sufficient for SCC differentiation. a, Schematic of the TCA 
cycle highlighting reactions catalyzed by OGDH and SDHA. b, GC-MS of intracellular αKG (left) 
and succinate (right) levels in shRenilla, shOgdh, and shSdha SCC lines, verifying expected 
changes in metabolite abundance upon knockdown. c, Growth of indicated SCC lines injected 
orthotopically. d, H3K27me3 immunofluorescence of indicated SCC lines. e-f, Quantification (e) 












In this study I discovered that environmental serine availability profoundly affects tumor 
initiation and SC fate. Pre-malignant EpdSCs that are destined to initiate tumors suppress de novo 
serine synthesis by increasing mitochondrial pyruvate consumption, resulting in endogenous 
serine auxotrophy. In WT EpdSCs, SSP activation facilitates aKG accumulation, which favors 
H3K27me3 demethylation and promotes terminal differentiation. The SSP also regulates SCC 
differentiation. In the presence of abundant serine, SSP inhibition triggered expansion of tSCs and 
promoted tumor growth. Conversely, enforcing serine synthesis using a Ser/Gly-free diet impaired 
tumor initiation in mice. Diet-mediated tumor suppression could be reversed by inhibiting aKG-
dependent dioxygenases, underscoring aKG-dependent differentiation as a major route of tumor 
suppression. These findings are likely to have relevance to humans, since xenografts were sensitive 
to Ser/Gly starvation and H3K27me3 levels correlated positively with tumor grade in human 
SCCs. These results shed light on how SCs integrate nutrient availability with chromatin dynamics 
in vivo (Fig 2.17). This work was recently published in Nature Cell Biology14. 
Recent evidence supports my finding that NAD+ regeneration is limiting for serine 
biosynthesis146. Previous studies revealed that environmental or genetic manipulations that impose 
mitochondrial redox imbalances subsequently impair amino acid biosynthesis146,147,150. Here, I find 
that endogenous changes in central carbon metabolism, such as those found in SOX2+ EpdSCs, 
similarly impair cytosolic NAD+ regeneration and amino acid biosynthesis. Collectively, these 
findings suggest that compartment-specific redox metabolism is likely to be an important regulator 
of cell fate decisions and nutrient stress responses. Although I cannot rule out the possibility that 
other mechanisms may restrict serine synthesis in pre-malignant EpdSCs, our data support a 






Fig 2.17 Extracellular serine controls epidermal stem cell fate and tumor initiation. Summary 
model of metabolic control of tumor initiation. Serine auxotrophy enforces oncogenic stem cell 
self-renewal but suppressing serine synthesis-derived αKG, which otherwise drives demethylation 




 Emerging evidence suggests that extracellular Ser/Gly restriction impairs tumor growth by 
imposing redox stress116,117 and limiting one-carbon units that support proliferation162. My data 
extend the tumor suppressive effects of Ser/Gly deprivation to tumor initiation, while providing 
an additional mechanism by which Ser/Gly restriction can antagonize tumorigenesis. The degree 
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to which Ser/Gly restriction affects endogenous serine synthesis, aKG production, and 
differentiation programs in other cell types is an important area for future investigation. 
Intriguingly, certain cancers harbor recurrent mutations in metabolic enzymes that poison 
aKG-dependent dioxygenases to suppress differentiation30,31,38,163. My data illustrate that even in 
the absence of such mutations, tSCs rewire intrinsic metabolic pathways to antagonize aKG-
dependent chromatin remodeling. While I cannot exclude regulation of other aKG-dependent 
dioxygenases, I find that environmental Ser/Gly availability contributes to H3K27me3 
demethylation, an established mediator of epidermal differentiation. 
 In conjunction with recent data that mutational status53, nutrient availability97,109,164 and 
other metabolic pathways165 can suppress aKG-dependent dioxygenases, our work supports the 
notion that aKG may act generally as a metabolic tumor suppressor. The pathways that contribute 
to aKG pools may vary in a cell-type and context-specific manner154,164,165.  It is intriguing to 
consider that while the TCA cycle produces aKG in mitochondria, the SSP generates aKG in the 
nucleo-cytosolic compartment, where it can act directly as a co-substrate for aKG-dependent 
dioxygenases. More broadly, my findings expose a way in which SCs balance metabolic demands 
for growth with those of regulating cell identity.  
Consistent with recent work17,116, I find that the SSP is critical for growth when 
extracellular serine is limiting. However, when extracellular serine is abundant, I find that the SSP 
is tumor suppressive. By contrast, certain established cancers including breast cancer and 
melanoma rely on SSP flux to maintain proliferation even in the presence of abundant extracellular 
serine154,161. Intriguingly, some of these tumors have evolved mechanisms such as EZH2 
overexpression166 to suppress differentiation. Thus, plentiful exogenous serine may generally 
support tumor initiation and growth both by repressing differentiation and supporting proliferation. 
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A key question from this work is how SCs are able to initiate a tumor in the face of serine 
auxotrophy. Both normal and malignant SCs reside in proximity to the vasculature, and the 
perivascular niche is critical for maintaining tSC self-renewal167,168. It is therefore tempting to 
speculate that this niche also represents a rich nutrient source that enables tumorigenic SCs to rely 
on extracellular serine and suppress differentiation. Dietary Ser/Gly restriction disrupts SC 
maintenance, thereby establishing serine availability as a key regulator of cell fate during tumor 
initiation and growth. These findings raise the possibility that targeting serine uptake may be a 
promising therapeutic avenue to eliminate oncogenic stem cells by blunting their self-renewal and 


























 Stem cells balance decisions of self-renewal and differentiation to maintain tissue 
homeostasis, and imbalances in this decision drive diverse pathologies including cancer and aging. 
Although numerous signaling and transcriptional pathways have been linked to stem cell fate 
regulation, the role of nutrients and metabolites in controlling stem cell behavior has been 
relatively less well explored. Moreover, whether or not endogenous metabolic pathways control 
key stem cell functions such as tumor initiation and lineage plasticity are poorly understood. Using 
the mammalian epidermis as a model system, I have explored these questions throughout the 
course of my thesis.  
In particular, I have focused on how availability and uptake of the nutrient serine is linked 
to intracellular metabolic pathways that control abundance of the metabolite αKG, a critical co-
substrate for chromatin modifying enzymes. I found that starving EpdSCs of serine triggers 
activation of the serine synthesis pathway, which drives αKG accumulation that is necessary and 
sufficient for epidermal differentiation and H3K27me3 demethylation. Accordingly, I found that 
serine availability controls the ability of a stem cell to initiate a neoplasm and properly respond to 
tissue injury. Finally, pre-malignant EpdSCs suppress endogenous serine synthesis to support their 
own self renewal. These findings have implications for therapeutic targeting of stem cells that 
initiate and sustain tumors and for enhancing wound repair. In this chapter I discuss three 
outstanding questions raised by my studies: the role of transporters in stem cell biology; the role 
of compartmentalized redox metabolism in controlling cell fate; and the mechanisms by which 




3.2 METABOLITE TRANSPORTERS AS REGULATORS OF STEM CELL FATE  
 Both in vitro and in vivo, I have found that limiting extracellular serine drives changes in 
stem cell behavior. In EpdSCs and SCC-SCs, it drives differentiation; in pre-malignant EpdSCs it 
drives growth arrest; and in HFSCs it promotes lineage plasticity. Moreover, measurements of 
serine uptake demonstrated that pre-malignant EpdSCs increased serine uptake relative to WT 
EpdSCs. These studies point to a critical role of serine abundance in mediating stem cell behaviors. 
In particular, in the IFE, it is tempting to speculate that the balance of extracellular serine 
abundance and intracellular serine uptake is an endogenous driver of EpdSC differentiation, such 
that differentiation is coupled to enhanced serine synthesis-dependent αKG production.  
 Within a tissue, abundance of a nutrient that a cell experiences is likely determined by two 
key parameters: non-autonomous control by tissue vasculature (supply) and cell autonomous 
control by transporter expression (consumption). First, proximity of a cell to and structure of the 
vasculature is likely to be a key determinant of nutrient availability, since the vasculature delivers 
and drains nutrients and oxygen to and from a tissue169,170. In the skin, stem cells reside on the 
basement membrane and are therefore in close proximity to blood and lymphatic vasculature. 
These vascular niches have been implicated in stem cell proliferation and self-renewal in the skin, 
although their role in regulating nutrient homeostasis has not been well explored91,167,168. Despite 
this, manipulation of the vasculature is likely to have pleiomorphic effects beyond nutrient 
regulation, given the critical role of perivascular niche in signaling to stem cells90,167,168. 
Nevertheless, the epidermis itself is avascular, and therefore it is likely that EpdSCs have greater 
access to nutrients than their differentiated counterparts due to their proximity to the vasculature. 
Secondly, nutrients are taken up into cells by transporters on the plasma membrane. 
Accordingly, it is tempting to speculate that transporter expression could determine the relative 
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abundance of a nutrient that a cell experiences, both based on the affinity of a particular transporter 
for its substrate and the amount of transporter a cell expresses. This effect has been well 
documented for glucose, where expression of the low affinity glucose transporter GLUT2 in 
metabolic organs enables sensing of circulating glucose levels to control systemic glucose 
homeostasis171. Moreover, acute regulation of GLUT1 plasma membrane localization enables 
rapid increases in glucose uptake upon growth factor stimulation88. Whether or not similar 
paradigms of nutrient sensing exist for other metabolites, such as serine, remains largely 
unexplored, and the role of transporters in controlling stem cell biology is not well understood.  
Serine is thought to be transported into cells by Solute Carrier Family 1A4 (SLC1A4) and 
1A5 (SLC1A5), both of which use sodium ion co-transport to drive uptake172,173. Serum serine 
levels are approximately 200±100 µM, and the Michaelis constants (an enzymatic measure of 
affinity) of SLC1A4 and SLC1A5 for serine are 100±20 µM and 250±40 µM, respectively172–174. 
Accordingly, SLC1A4 is predicted to be a high affinity serine transporter relative to SLC1A5 (Fig. 
3.1a). Given increased serine uptake in pre-malignant SOX2+ EpdSCs relative to WT EpdSCs, I 
asked whether or not this might be linked to differential expression of serine transporters. 
Consistent with its role as a high affinity serine transporter, I found that SOX2+ EpdSCs expressed 
higher levels of Slc1a4 mRNA and protein in vitro (Fig. 3.1b). Intriguingly, in vivo, SLC1A4 
expression is restricted to EpdSCs within both WT and SOX2+ epidermis, although its expression 
remains higher in SOX2+ EpdSCs (Fig. 3.1c). That SLC1A4 is only expressed in stem cells within 
the epithelium raises the possibility that differentiation is endogenously coupled to a decrease in 
serine uptake and an increase in serine synthesis, driving αKG-dependent differentiation. 
Importantly, serine itself is an essential metabolite for epidermal barrier formation due to its role 
in sphingolipid biosynthesis175,176, suggesting that differentiation would impose a significant 
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demand for serine synthesis in the absence of the ability of differentiated cells to consume serine 
from extracellular sources. Consistently, patients with PHGDH deficiency exhibit impaired 
epidermal differentiation that is associated with defects in sphingolipid biosynthesis176,177.  
 
Fig. 3.1 SLC1A4 as a putative regulator of EpdSC fate. a, Enzymatic parameters of SLC1A4 
and SLC1A5, two potential serine transporters. b, mRNA (left) and Western blot (right) of serine 
transporters in cultured EpdSCs. c, In vivo SLC1A4 expression. Dashed line indicates basement 
membrane, solid line indicates air-epithelial interface. d, Potential model for how serine 
availability and transport endogenously regulate epidermal differentiation. 
 
Altogether, the combination of EpdSC proximity to the vasculature and restricted 
expression of SLC1A4 suggests a model wherein apparent serine availability endogenously 
controls epidermal differentiation (Fig. 3.1d). This would be consistent with our data that dietary 
Ser/Gly restriction increases EpdSC differentiation. Future studies should be aimed at 
manipulation of SLC1A4 to determine its role in epidermal differentiation, both via loss of 
function studies and overexpression of SLC1A4 mutants with varying affinities for serine173 in 
differentiating cells. Reconstitution of SLC1A4 in cultured WT EpdSCs as well as cell free studies 
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will enable us to interrogate its biochemical function as a serine transporter in the epidermis.  If 
SLC1A4 expression determines differentiation, I might expect that its overexpression in 
suprabasal cells would block their differentiation via suppression of serine synthesis dependent 
αKG production, while maintaining sphingolipid synthesis. 
More broadly, given the restricted nature of SLC1A4 expression it is intriguing to consider 
whether or not a “transporter code” exists within tissues, such that the cohort of transporters 
particularly cell types express determines their function and fate. Moreover, transporters are 
appealing therapeutic targets given their plasma membrane localization and the possibility of 
developing competitive inhibitors for their substrates. Altogether, my functional studies on 
extracellular Ser/Gly restriction in Chapter 2 coupled with preliminary expression data presented 
here warrant further investigation of amino acid transporters as critical regulators of physiological 
stem cell functions.  
 
3.3. COMPARTMENTALIZED REDOX METABOLISM AS A REGULATOR OF CELL 
FATE.  
 A major contribution of my work is the identification of cytosolic redox status as a 
determinant of serine synthesis in EpdSCs. Briefly, the first step of serine synthesis by PHGDH 
requires the reduction of NAD+ to NADH. Accordingly, sustaining serine synthesis requires a 
mechanism to regenerate NAD+ from NADH in the cytosol, which in most cells is accomplished 
via the conversion of pyruvate to lactate by lactate dehydrogenase178. I found that pre-malignant 
EpdSCs restricted serine synthesis by decreasing the conversion of pyruvate to lactate, instead 
oxidizing pyruvate in the TCA cycle. Notably, increasing NAD+ regeneration was sufficient to 
drive stem cell differentiation, presumably in part by enhancing serine synthesis. Interestingly, in 
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the intestinal crypt, blocking pyruvate entry into the mitochondria and subsequently shunting it to 
lactate enhances stem cell proliferation and self-renewal179–181. These studies provide evidence that 
compartmentalized redox status is a lineage specific determinant of cell fate and nutrient 
dependencies.   
 Previous studies have linked redox status to amino acid biosynthesis. Of note, these studies 
found that genetic and pharmacological suppression of mitochondrial NAD+ regeneration was 
sufficient to impair aspartate and serine biosynthesis146,147,150,182. Our work, in contrast, is the first 
demonstration of endogenous metabolic rewiring via changes in pyruvate fate controlling redox 
homeostasis. Moreover, they place these previous findings in the physiological context of tumor 
initiation and stem cell fate and provide evidence for distinct functions of cytosolic and 
mitochondrial redox homeostasis. Studying the role of redox metabolism in other physiological 
stem cell functions such as during wound healing may be of interest for future studies.  
 I suggest that in part, enhancing cytosolic NAD+ regeneration drives differentiation by 
enhancing αKG synthesis via serine synthesis. Future studies can take advantage of LbNOX 
expression, which I established and validated in the epidermis, to genetically enhance NAD+ 
regeneration in order to further investigate this process. Moreover, LbNOX can also be targeted to 
the mitochondria (mitoLbNOX)148, and comparative analysis of the effects of mitoLbNOX and 
LbNOX may enable us to understand the physiological functions of compartmentalized redox 
metabolism in EpdSCs. It will be of particular interest to understand whether or not there are αKG-
independent effects of cytosolic NAD+ regeneration on stem cell fate, such as through regulation 




3.4 αKG AS A REGULATOR OF STEM CELL FATE IN THE EPIDERMIS  
 I found that extracellular serine abundance controls stem cell fate by regulating αKG levels. 
Limiting extracellular Ser/Gly triggers activation of the serine synthesis pathway, which 
subsequently leads to αKG accumulation that can drive EpdSC differentiation and H3K27me3. 
These studies build on previous work from our lab and others showing that the H3K27me3 
methyltransferase EZH2 is essential for EpdSC self-renewal and that the demethylase JMJD3 is 
essential for differentiation155,156,187. Nevertheless, as discussed in Chapter 1, it remains 
challenging to understand how αKG mediates specific effects, given that multiple intracellular 
dioxygenases consume it as part of their reaction cycle. Indeed, although I find that 
pharmacological inhibition of JMJD3 is sufficient to reverse Ser/Gly starvation induced 
differentiation, and that H3K27me3 levels correlate with αKG-induced differentiation, it remains 
possible that additional dioxygenases are important in differentiation. For example, similar to 
H3K27me3, DNA methylation has been shown to be critical for EpdSC self-renewal188, suggesting 
that TET enzymes that demethylate DNA may also play a role in αKG-dependent differentiation. 
Nevertheless, this work is the first to establish αKG as a regulator of adult stem cell behavior, 
building on work in embryonic stem cells that αKG is a key determinant of stem cell fate29.  
 Multiple cancers harbor recurrent mutations in metabolic enzymes, such as isocitrate 
dehydrogenase 1 and 2 (IDH1/2) and succinate dehydrogenase (SDH) that result in accumulation 
of so-called oncometabolites that poison αKG-dependent dioxygenases. Notably, these 
oncometabolites largely function by locking stem cells in a hyperproliferative self-renewing 
state21. Consistently, αKG has been shown to suppress tumorigenesis and drive differentiation in 
multiple cancers including leukemia, pancreatic cancer, and intestinal cancer52,53,111. Thus, our 
work adds to a growing body of literature suggesting that αKG acts as a metabolic tumor 
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suppressor. Additionally, it is consistent with previous work showing that environmental 
constraints such as glutamine limitation and hypoxia can limit αKG-dependent dioxygenase 
function52,97,109, suggesting that cancer cells can engage multiple mechanisms to evade the tumor 
suppressive effects of αKG. Moreover, it provides evidence that stem cells can rewire endogenous 
metabolic pathways to limit αKG production, such that even under serine limited conditions pre-
malignant EpdSCs can prevent differentiation by suppressing serine synthesis.  
 An important question is understanding whether or not it will be feasible to enhance αKG 
production to suppress tumorigenesis. While this represents an appealing route forward, it should 
be noted that αKG accumulation may not always be beneficial. For example, in breast cancer, αKG 
promotes metastatic colonization of the lung by enhancing activity of αKG-dependent collagen 
hydroxylases164. In pediatric ependymomas, αKG was recently shown to be critical in establishing 
epigenomic programs that support proliferation104. These studies highlight the importance of 
understanding the specific mechanisms by which αKG mediates its diverse effects, so as to better 
refine our ability to target this critical metabolic axis.  
 
3.5 CONCLUSIONS 
 In this thesis, I aimed to explore metabolic control of stem cell function in the skin. In 
doing so, I uncovered the mechanisms by which nutrient availability is integrated with stem cell 
fate decisions during tumor initiation and progression and wound repair. I anticipate that these 
findings will have implications beyond the skin. It may be of particular interest to study the links 
between αKG and amino acid uptake in stem cells that initiate neoplasms driven by IDH mutations, 
such as those of the blood and brain. Additionally, I anticipate that understanding the links between 
endogenous metabolic pathways and transcriptional programs in stem cells will be broadly 
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relevant in pathologies outside of cancer, including inflammatory diseases, wound healing, 
diabetes and degenerative diseases. Finally, building on our knowledge of the mechanisms by 
which serine, αKG and cell fate are linked will enable directed therapies to enhance epidermal 
wound repair while suppressing tumorigenesis.  
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MATERIALS AND METHODS 
Cell culture. Primary EpdSCs from WT and SOX2+ mice, HRasG12V transduced EpdSCs, and SCC lines 
were grown under standard tissue culture conditions, 37 oC and 7.5% CO2. Cells were cultured in E-low 
calcium (50 μM Ca2+) medium (E-low) made in house from DMEM/F12 medium supplemented with 15% 
chelated FBS, 5 μg/mL insulin, 5 μg/mL transferrin, 2 nM triiodothyroxine, 40 μg/mL hydrocortisone and 
10 nM cholera toxin. For all experiments, cells were switched from E-low growth medium to E-low lacking 
pyruvate, aspartate, glutamate, and glutamine reconstituted with 4 mM glutamine, 25 mM glucose, 15% 
chelated dialyzed FBS (GeminiBio), and ±0.32 mM Ser/Gly (experimental E-low medium). A431 SCCs 
were grown in DMEM supplemented with 10% FBS and 1 mM sodium pyruvate. SCC9 SCCs were grown 
in E-low medium supplemented to 1.5 mM Ca2+. A mix of male and female cells were used for all studies. 
Independently derived littermate lines were used for comparisons. Unless noted in legends, WT-1 and 
SOX2-1 lines were used.  
Mice. All animal experiments were performed in the AAALAC-accredited Comparative Bioscience Center 
at the Rockefeller University. Experiments were in accordance with NIH guidelines for Animal Care and 
Use, approved and overseen by The Rockefeller University’s Institutional Animal Care and Use Committee. 
Rosa26-CAG-loxP-stop-loxP-Sox2-IRES-eGFP mice were donated by J. Que and maintained in a 
B6/svev129 mixed background. Krt14-cre(tg), Krt14-creER(tg), and Krt10-H2B-mRFP(tg) mice were 
maintained in a CD-1-ICR background. Sox9-CreER;R26-LSL-YFP mice were maintained in a mixed 
B6/CD1 background. For analysis of WT and SOX2+ mice, a mix of males and females were used. Krt14-
CreER;R26-LSL-Sox2-IRES-GFP and Sox9-CreER;R26-LSL-YFP mice were treated with 5 100 μL doses 
of  2% w/v tamoxifen (Sigma) beginning at P50. For tumor allografts, 6-8 week old female Nude (Nu/Nu) 
mice were used. For DMBA/TPA experiments, P60 female FvB mice were used. 
Primary culture derivation. P0 mice were euthanized by decapitation, backskin was dissected off and 
incubated in a 1:1 mix of dispase and PBS overnight at 4 oC. Epidermis was removed from the dermis and 
incubated in a 1:1 mix of 0.25% trypsin/EDTA and versene for 10 min at room temperature. The epidermal 
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fraction was mechanically dissociated to a single cell suspension, filtered through a 40 μm filter and 
cultured in E-low medium.  
Growth curves. 5000 WT, SOX2+ or HT-SCC cells were plated in triplicate into a black 96 well plate 
(Nunc). The next day (day 0), one plate was fixed with 4% PFA for 10 min. Remaining cells were treated 
with indicated medium/reagent, and at indicated times were subsequently fixed, stained with DAPI, and 
counted using a BioTek Cytation5. For chemical treatments, cells were pre-treated for 4 h prior to switching 
to control or serine/glycine (Ser/Gly)-free experimental E-low medium. For partial Ser/Gly starvation 
experiments, cells were cultured in medium with 17.065 mg/L serine and 12.19 mg/L glycine. Population 
doublings were calculated as the log2 fold change in cell number relative to day 0.  
Scratch wound. HFSCs were seeded in a 6 well plate. When cultures were confluent, cells were washed 
once with PBS and switched into control or ser/gly free medium. A P200 pipet tip was dragged once down 
the length of each well to generate a wound, and cells were imaged using phase contrast microscopy and 
indicated time points.  
In vitro drug treatments. Drugs were added at the following concentrations: a-ketobutyrate 1 mM, 
dichloroacetate 5 mM, UK-5099 500 nM, pyruvate 2 mM, lactate 2 mM, formate 1 mM, dimethyl-a-
ketoglutarate 4 mM, 4 mM, eGSH 1 mM, Trolox 500 nM, GSK-J4 10 µM, GSK-343 10 µM, Nutlin-3a 10 
µM. 
Nutrient uptake. 150,000 WT or 300,000 SOX2+ cells were seeded into 6 well plates (Corning). The 
following day, medium was aspirated and replaced with 1 mL of experimental E-low medium containing 
Ser/Gly. At the same time, 1 mL of medium was added to a control 6 well plate lacking cells. 24 h later, 
media was collected and spun at max speed at 4 oC for 20 min. 50 µL of the supernatant was added to 1 mL 
of ice-cold 80% methanol supplemented with 2 μM deuterated 2-hydroxyglutarate (D-2-hydroxyglutaric-
2,3,3,4,4-d5 acid (d5-2HG)) as an internal standard and analyzed by mass spectrometry. Glutamine 
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consumption, glutamate secretion and lactate secretion were measured using a YSI 2950 series 
biochemistry analyzer (YSI Life Sciences). Metabolite consumption and secretion was determined relative 
to fresh medium and the values were normalized to the average protein content in each condition where 
indicated. 
 
Serine standard curve. Serine (0-20 nmol) was dissolved in 50 μL of water and mixed with ice-cold 80% 
methanol supplemented with d5-2HG. After overnight incubation at -20°C, the serine standards were dried 
in an evaporator (Genevac EZ-2 Elite), derivatized as described in GC-MS metabolite profiling and 
analyzed using an Agilent 7890A GC coupled to Agilent 5975C mass selective detector. A standard curve 
was obtained by plotting d5-2HG-normalized serine peak area against the amount serine. The linear 
regression equation was calculated by the least squares method using Microsoft Excel.  
 
Estimation of serine synthesis. To quantify the amount of serine consumption, the MS peaks representing 
serine were extracted and integrated using MassHunter software, normalized to the internal standard (d5-
2HG) peak area and quantified against the serine standard curve. The calculated values were normalized to 
the average protein content of all wells in each condition (µmol serine/mg protein). Serine biosynthetic 
demand in the absence of exogenous Ser/Gly was estimated using a serine standard curve to calculate serine 
uptake (from Fig. 1c) in the presence of Ser/Gly and serine secretion in the absence of Ser/Gly, while 
intracellular glutamine availability was estimated using a YSI analyzer as glutamine consumption minus 
glutamate secretion. Since serine synthesis produces a mole of aKG per mole of serine, the fraction of 
intracellular glutamine used to meet serine biosynthetic demand approximates the fraction of glutamine 
used to produce aKG via this pathway. See Supplementary Tables 2 and 3 for more information.  
 
GC-MS metabolite profiling. For all metabolite experiments, 150,000 WT or 300,000 SOX2+ cells were 
seeded in 6-well plates under standard culture conditions and changed into the corresponding experimental 
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E-low media the next day. For isotope tracing experiments, cells were cultured for 4 h in indicated 
experimental E-low medium reconstituted with uniformly labeled 13C-serine, glycine, glucose or glutamine 
(Cambridge Isotope Labs) following 16 hours of culture in experimental E-low medium with or without 
Ser/Gly. For serum, blood was collected from the retro-orbital sinus and allowed to clot on ice for 30 min. 
Samples were then spun at 1,000 g for 10 min and supernatant (serum) was collected. Metabolites were 
extracted with 1 mL of ice-cold 80% methanol supplemented with d5-2HG. 
After overnight incubation at -80°C, cell lysates were centrifuged at 21,000 g for 20 min and protein-free 
supernatants were dried in an evaporator (Genevac EZ-2 Elite). Metabolites were resuspended in 50 μL of 
40 mg/mL methoxyamine hydrochloride (Sigma) in pyridine (ThermoFisher) by incubation at 30°C for 2 
h and further derivatized by addition of 80 μL of MSTFA (ThermoFisher) and 70 μL ethyl acetate (Sigma). 
After 30 min incubation at 37°C, samples were analyzed using an Agilent 7890A GC coupled to Agilent 
5975C mass selective detector. The GC was run in splitless mode using constant helium gas flow at 1 
mL/min. A microliter of derivatized sample was injected onto an HP-5MS column and the GC oven 
temperature ramped from 60°C to 290°C over 25 min.  
GC-MS analysis. Peaks representing metabolites of interest were extracted and integrated using 
MassHunter software (Agilent Technologies) and verified relative to known spectra for each metabolite. 
The following ions were used for quantification of metabolite levels: d5-2HG m/z 354; alanine, m/z 218; 
aKG, m/z 304; asparagine, m/z 231; aspartate, m/z 334; citrate, m/z 465; cysteine, m/z 322; fumarate, m/z 
245; glutamate, m/z 363; glutamine, m/z 362; glycine, m/z 276; isoleucine, m/z 260; leucine, m/z 260; 
malate, m/z 335; methionine, m/z 250; phenylalanine, m/z 294; proline, m/z 216; serine m/z 306; succinate, 
m/z 247; threonine, m/z 320; tryptophan, m/z 405; tyrosine, m/z 382; and valine, m/z 246; pyruvate, m/z 115; 
lactate m/z 219. All values were normalized to both the internal standard peak area and the protein content 
of triplicate samples. Enrichment of 13C was determined by quantifying the abundance of the following 
ions: citrate, m/z 465-482; glycine, m/z 276-286; and serine, m/z 306-317. Correction for naturally occurring 
isotopes was performed using IsoCor software189. 
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NAD+/NADH ratio quantification. The NAD+/NADH ratio was quantified using an enzymatic 
colorimetric Abcam kit according to manufacturer’s instructions. Briefly, cells were lysed with 450 µL 
NADH/NAD extraction buffer and then spun for 5 min at 4oC at maximum speed. Supernatant was filtered 
through a 10 kDa spin column (BioVision) and 200 µL was used for total NAD+ and NADH quantification. 
The remaining extract was heated at 60oC for 30 min to decompose NAD+. 50 µL of sample was mixed 
with 100 µL of reaction mixture and incubated for 5 min at room temperature. 10 µL of developing solution 
was added and the reaction was incubated for 1 h at room temperature. Absorbance was measured at 450 
nm using a BioTek Cytation 5 plate reader and NAD+ and NADH amounts were calculated using a standard 
curve of purified NADH. The NAD+/NADH ratio was calculated as (NAD(H)total – NADH)/NADH.  
Immunofluorescence and image analysis. For immunofluorescence, samples were dissected off of mice, 
were pre-fixed in 4% PFA for 1 h at 4°C and then incubated with 30% w/v sucrose overnight, embedded in 
Optimal Cutting Temperature (OCT) compound (Tissue Tek), and sectioned at a thickness of 12 μm. For 
in vitro immunofluorescence, cells were seeded into fibronectin coated glass chamber-slides (Millipore), 
and fixed for 10 min in 4% PFA at room temperature. To determine HFSC proliferation in waxing 
experiments, skin was scraped to remove fat, incubated in 2.5 U/mL dispase + 20 mM EDTA for 2 hr at 
37oC, and then HFs were separated from the epidermis manually. Samples were blocked at room 
temperature in Gelatin Block (2% fish gelatin, 5% normal donkey serum, 1% bovine serum albumin, 0.3% 
Triton, in PBS). Samples were incubated with primary antibody overnight at 4°C, washed in PBS, and 
exposed to secondary antibody for 1 h at room temperature. Samples were mounted in ProLong Gold with 
DAPI (Life Tech) prior to imaging. The following primary antibodies and dilutions were used: GFP 
(chicken, 1:2000, Abcam), GFP (goat, 1:1000 VWR), K5 (guinea pig, 1:500, E. Fuchs), K10 (rabbit, 
1:1000, Covance), RFP (rat, 1:1000, Chromotek), RFP (goat, 1:500, MYBioSource), K14 (rabbit, 1:1000, 
E. Fuchs), K14 (chicken, 1:1000, Covance), Involucrin (rabbit, 1:1000, Covance), SOX2 (rabbit, 1:300, 
Abcam), cleaved caspase 3 (rabbit, 1:200, Cell Signaling), integrin-a6 (rat, 1:2000, eBioscience), 
H3K27me3 (rabbit, 1:500, Millipore), FLAG M2 (mouse, 1:1000, Sigma), CD44 (rat, 1:200, BD 
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Bioscience), Ki-67 (rabbit, 1:200, Cell Signaling), K24 (Fuchs lab, 1:5000), KLF5 (goat, 1:100, R&D), 
SLC1A4 (rabbi, 1:200, Cell Signaling). Secondary antibodies were conjugated to Alexa FluorTM 488, RRX, 
or 647 (1:1000, Life Technologies A-11006). Phalloidin conjugated to Alexa FluorTM 564 or 647 (165 nM 
working concentration, ThermoFisher) were used and stained simultaneously with secondary antibodies. 
Images were captured on a Zeiss Axioplan2 using a Plan-Apochromat 20x/0.8 air objective or 40x/0.8 oil 
immersion objective. Images were processed using ImageJ and Adobe Photoshop CS5. See Reporting 
Summary for antibody catalog numbers. 
To quantify fluorescence in SCCs of progenitor and differentiated cell markers, tumor cells were masked 
on GFP (for K14, K10 and involucrin) or DAPI/H2B-mRFP (for H3K27me3) and pixel intensity was 
analyzed within the mask on the marker of interest. In the absence of a mask for cells of interest, 
fluorescence was quantified manually through ROI selection. To quantify mitotic spindle axis, a straight 
line was drawn between the middle of two daughter nuclei marked by K14, and the angle between this line 
and the basement membrane, as stained by keratin-14, was quantified. Mitotic angles < 30o were classified 
as planar, and angles >30o were classified as nonplanar.  
Immunohistochemistry. All human samples were derived from commercially purchased, de-identified 
paraffin embedded tissue arrays (Biomax SK802b, HN803e). Arrays were baked at 60oC for 30 min and 
then deparaffinized by washing 2x10 times in Citrus Clearing Solvent (ThermoFisher) followed by 2x10 
washes in 100% ethanol (EtOH), 1x10 wash in 95% EtOH, and 1x10 wash in 70% EtOH. Antigen retrieval 
was then performed in pH 6.0 Citrate (Vector Laboratories) by heating slides to 125oC for 30 s and 90oC 
for 10 s in a pressure cooker. Slides were stained according to VECTASTAIN® Elite® ABC Universal 
PLUS Kit manufacturer instructions (Vector Laboratories). Briefly, slides were permeabilized for 5 min in 
0.1% TBS-T, blocked in BLOXALL peroxidase block for 10 min and horse serum for 20 min. Arrays were 
incubated in primary antibody (H3K27me3 rabbit, 1:500, Millipore) overnight at 4oC. The next day, slides 
were incubated with secondary antibody (Horse anti-mouse/rabbit IgG, biotinylated) for 30 min at room 
temperature. Slides were incubated in VECTASTAIN Elite ABC Reagent for 30 min at room temperature, 
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and then in a 1:1 mixture of ImPACT® DAB EqV Reagent 1 (Chromogen) and Reagent 2 (Diluent) for 2 
min. After development, slides were incubated in hematoxylin (Sigma) for 1 min, washed 3x in water, 
washed 1x in acid alcohol (1% HCl in 95% EtOH), washed 3x in water, washed 1x in Bluing Reagent 
(Fisher), washed 1x in water, and then dehydrated by washing 10x 70% EtOH, 10x 95% EtOH, 2x10 100% 
EtOH, 2x10 Citrus Clearing Solvent. Slides were mounted with Cytoseal 60 (ThermoFisher). Images were 
captured using a BioTek Cytation 5 using a 4x or 20x air objective. See Reporting Summary for antibody 
catalog numbers. 
To score arrays for H3K27me3 intensity, investigators were blinded to tumor stage, lineage and anatomic 
location. Within a tissue core, lymphocytes were used as an internal control for high H3K27me3 staining. 
Staining intensity within tumor cells was scored “high” if intensity was at least ~70% as intense as 
lymphocytes, “moderate” if intensity was ~30-70% as intense as lymphocytes, or “weak” if staining was 
<30% as intense as lymphocytes. After scoring, investigators were unblinded to bin scoring results based 
on histopathological grade. Images were processed in ImageJ and Photoshop.  
Hematoxylin & eosin. Slides were washed in water, incubated in hematoxylin for 2 min, washed in water 
3x, washed once in acid alcohol, washed twice in water, washed once in Bluing reagent, and washed once 
in water. Slides were subsequently dehydrated with 10 washes each in subsequent 80%, 95% and 100% 
EtOH, followed by eosin staining for 1 minute, 2 x 20x washes in 100% EtOH and 2 x 20x washes in Citrus 
Clearing Solvent. Slides were mounted with Cytoseal 60 and imaged on a Zeiss Axioplan2 using a Plan-
Apochromat 20x/0.8 air objective. Images were processed in ImageJ and Photoshop.  
Western Blot. Triplicate wells were lysed in chilled RIPA buffer containing cOmplete protease inhibitors 
and PhoSTOP phosphatase inhibitors (Roche). Protein was quantified using a Pearce BCA protein 
quantification kit. 15 μg of protein was loaded for SDS-PAGE and standard western blotting procedures. 
For histone extraction, 1 x 106 cells were suspended in Laemmli buffer and sonicated 15X, 30 s on/off. b-
mercaptoethanol and bromophenol blue were added, samples were boiled, and 6 µL was loaded for standard 
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western blotting procedures. Membranes were blocked in LiCOR blocking buffer. Membranes were 
incubated in primary antibody overnight in blocking buffer with 0.2% Tween-20 at 4oC, and incubated in 
secondary antibody diluted in blocking buffer with 0.2% Tween-20 and 0.01% SDS for 1 h at room 
temperature. The following primary antibodies and dilutions were used: PHGDH (rabbit, 1:2000, Sigma), 
PSAT1 (mouse, 1:500, Sigma) PSPH (rabbit, 1:500, Sigma), SHMT1 (rabbit, 1:1000, Cell Signaling), 
SHMT2 (rabbit, 1:1000, Cell Signaling), OGDH (rabbit, 1:1000, ProteinTech), SDH-A (mouse, 1:1000, 
abcam), H3K27me3 (rabbit, 1:1000, Millipore), a-tubulin (mouse, 1:10000, Sigma), total H3 (mouse, 
1:10000, abcam), b-actin (rabbit, 1:1000, Cell Signaling), SLC1A4 (rabbit, 1:1000, Cell Signaling). The 
following LiCOR secondary antibodies were used, all at 1:10000: IRDye 800CW donkey anti-mouse IgG, 
IRDye 800CW donkey anti-rabbit IgG, IRDye 680 LT donkey anti-mouse IgG, IRDye 680LT donkey anti-
rabbit IgG. Membranes were imaged via fluorescence on an Odyssey CLx Imager and processed using 
Adobe Photoshop CS5. See Reporting Summary for antibody catalog numbers. 
qRT-PCR. Triplicate wells were lysed in 200 µL TRIzol. RNA was extracted using a Zymo Direct-zol 
RNA miniprep kit, and 100 ng of RNA was used for cDNA synthesis with a SuperScript VILO cDNA 
synthesis kit (ThermoFisher). cDNA was diluted 1:5 for qPCR. cDNAs were mixed with indicated gene-
specific primers listed in Supplementary Table 7 and SYBR green PCR Master Mix (Sigma), and qRT-
PCR was performed on an Applied Biosystems 7900HT Fast Real-Time PCR system. Values were 
normalized to expression of b-actin.  
EdU incorporation. Mice were treated with 0.02 CC of 5 mg/mL EdU for 1 hour prior to sacrifice. EdU 
staining was performed following incubation of slides with secondary antibody. AF-647 azide, copper 
sulfate and EdU additive buffer and reaction buffers (Life Technology) were added to slides. Slides were 
incubated for 20 min at room temperature, washed and mounted for imaging.  
Tumor allograft, xenograft and growth curves. 200,000 mouse (HrasG12V;Tgbr2 cKO)  or human (SCC9, 
or A431) SCC cells diluted 1:1 in growth factor-reduced, phenol red-free Matrigel (Corning) were injected 
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intradermally into the backs of Nude mice. For shSdha and shOgdh experiments, mice were treated with 
100 mg/L doxycycline and 2% w/v sucrose in drinking water starting 5 days after grafting. For GSK-J4 
treatment, mice were treated daily for five days intraperitoneally with 10 mg/kg GSK-J4, beginning 5 days 
after grafting. For rapamycin treatment, mice were treated daily for five days intraperitoneally with 4 mg/kg 
rapamycin, beginning 5 days after grafting.  Tumors were measured at indicated time points. Tumor size 
was measured using a digital caliper, and volume was calculated using the formula (π(length x width)2)/6.  
Serine/glycine free diet. Purified control amino acid diet (5CC7) and diet lacking serine and glycine 
(5BJX) (WF Fisher and Sons) were formulated as previously described116,117. Mice were maintained on 
diets for at least two weeks prior to initiating experiments. Pregnant females were placed on diet on the day 
of plug.  
DMBA/TPA two step chemical carcinogenesis protocol. P60 female WT FvB mice were placed on 
control or serine/glycine free diet. Two weeks later, mice were treated topically with a single 100 µL dose 
of 400 nmol DMBA (Sigma) diluted in acetone. Beginning the following week, mice were treated 2x/week 
topically with 100 µL of 20 nmol TPA (Sigma) diluted in ethanol and monitored for tumors.  
Wounding. Second telogen mice were used for wounding experiments. Mice were anesthetized with 
isofluorane and shaved for partial thickness and full thickness wounds. For partial thickness wounding, skin 
was gently stretched and a Dremel tool with a polishing tool was used to make abrasions of the epidermis 
by polishing the skin 4-5 times (100 series rotary tool and 520 polishing tool from Dremel Inc.). For full 
thickness wounding, a 6 mm punch biopsy (Miltex) was taken. For depilation, molten wax was applied onto 
the hair coats and peeled off after hardening.  
CRISPR/Cas9 editing of SCC cells. Guide RNA (gRNA) targeting the second and fourth exons of Phgdh 
were designed using GuideScan software70. Synthetic gRNAs, negative control gRNA, Atto550-trRNA, 
and recombinant Cas9 were purchased from IDTdna. gRNA:trRNA:Cas9 complexes were assembled and 
transfected into SCC cells following manufacturers protocol (IDTdna.com: Cationic lipid delivery of 
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CRISPR ribonucleoprotein complexes into mammalian cells) using RNAiMAX (ThermoFisher) reagent as 
the transfection reagent. 48 h post transfection single GFP+/Atto550+/DAPI- cells were sorted into 96 well 
plates and allowed to grow into clonal cell lines. To screen cells for Phgdh knockout, genomic DNA was 
isolated from each clone. Short PCR amplicons including the gRNA target region were generated, barcoded, 
sequenced in a multiplex fashion on an Illumina MiSeq Nano using a modified version of the 16S 
metagenomics sequencing library preparation protocol from illumima. Knockout was confirmed by 
western blot. sgRNA sequences are provided in Supplementary Table 6. 
shRNA mediated knockdown and viral infection. Following Phgdh hairpin screening via transient 
transfection, efficient hairpins were subcloned into pLKO-H2B-mRFP1 vectors. shOgdh and shSdha 
hairpins were packaged into LT3-GEPIR doxycycline inducible vectors53 (donated by S. Lowe) and 
validated following culture of cells in 1  µg/mL doxycycline hyclate (Sigma) for 24 h. For LbNOX 
expression, LbNOX-Flag (Addgene #75285) was amplified and subcloned with an N-terminal P2A site into 
pLKO-H2B-mRFP1. Vectors were packaged into lentivirus using calcium chloride transfection of 293TN 
cells (Invitrogen) with packaging plasmids pMD2.G and pPAX2 (Addgene #12259 and #12260, 
respectively). Viral supernatant was collected 46 h after transfection and filtered through a 0.45 μm filter. 
Cells were then transduced and two days later were purified using fluorescence associated cell sorting 
(FACS) based on mRFP1 expression. For shRenilla, shOgdh, and shSdha lines, infected cells were selected 
using 1  µg/mL puromycin for 24 h. shRNA sequences are provided in Supplementary Table 5.  
Statistics and Reproducibility  
Statistical analyses were performed using Prism 7 and 8 (Graphpad) software. All in vitro experiments 
shown were repeated at least twice in triplicate with similar results, and representative data are shown unless 
otherwise indicated. All in vivo experiments were repeated in at least three biological replicates with similar 
results. Unpaired two-tailed Student’s t-tests were used to ascertain statistical significance between two 
groups. One-way ANOVA was used to assess statistical significance between three or more groups with 
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one experimental parameter, while two-way ANOVA was used to assess statistical significance between 
groups with two experimental parameters. See Fig. legends for more information on statistical tests. Mice 
were randomly allocated to control or experimental conditions. Experimenters were not blinded to 
conditions during data collection or analysis, except for scoring of H3K27me3 staining by IHC, where 




Table 2.1. Serine standard curve data  


























Table 2.2. Extracellular glutamine, glutamate and serine data  
 
 
Parameter Mean (n = 6) Standard Deviation 
Gln consumption (mmol/mg 
protein)  6.439 0.4965 
Glu secretion (mmol/mg protein) 1.14 0.02147 
Intracellular Gln (Gln consumed 
- Glu secreted) (mmol/mg 
protein) 
5.299 0.4858 
Ser consumption (mmol/mg 
protein) 0.5164 0.1203 
Ser secretion (mmol/mg protein) 0.05072 0.01014 
Serine synthesis (Ser 
consumption + Ser secretion) 
(mmol/mg protein) 
0.5671 0.1193 
Fraction of Intracellular Gln (Ser 











Table 2.3 shRNA sequences  
shScramble CAACAAGATGAAGAGCACCA 
shPhgdh-1 CCGAATGCAATCCTTTGGAAT  
























Table 2.4 sgRNA sequences 
sgPhgdh-A AATGAGGCCTTCACAGTCCT  
sgPhgdh-B CCAGAACTTACTTCATGACT   















































Krt-14_F CGCCGCCCCTGGTGTGG  
Krt-14_R ATCTGGCGGTTGGTGGAGGTCA  
Krt-5_F AACATTTTGGGGTCTGGGTCAC  
Krt-F_R GGCCCACAGAGACTGCTTCTTT  
Lor_F TCACTCATCTTCCCTGGTGCTT  
Lor_R GTCTTTCCACAACCCACAGGA  























Actin_F GCTCTTTCCAGCCTTCCTT  
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